Improved beta-glucuronide linker-drug conjugate
The beta-glucuronide linker in ADCs addresses stability and solubility issues, providing effective cancer treatment with improved efficacy and reduced side effects by leveraging beta-glucuronidase activity and hydrophilicity.
Patent Information
- Application Number
- PCT/KR2026/096874
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Existing antibody-drug conjugates (ADCs) face issues such as reduced in vivo pharmacokinetic stability, non-specific tissue accumulation, low solubility, and aggregation due to hydrophobic drugs or linker structures, leading to reduced therapeutic efficacy and increased side effects.
An ADC comprising a beta-glucuronide linker that is selectively cleaved by beta-glucuronidase, which is stable in plasma and has excellent hydrophilicity, without polyethylene glycol (PEG), enhancing cancer treatment efficacy.
The ADC achieves improved cancer treatment efficacy with low side effects, stable plasma stability, and enhanced hydrophilicity, while avoiding PEG-related drawbacks.
Smart Images

Figure KR2026096874_19112026_PF_FP_ABST
Abstract
Description
Improved beta-glucuronide-linker drug conjugate
[0001] The present invention relates to an antibody-drug conjugate (ADC) in which an antibody and a drug are combined via a linker. In particular, the invention relates to an ADC having a structure capable of inducing the release of a drug under specific physiological conditions, such as a tumor microenvironment, by including a beta-glucuronide linker that is selectively cleaved by beta-glucuronidase. Furthermore, the present invention provides medical and pharmaceutical uses for such an ADC for the treatment of cancer, and provides a method for treating cancer comprising administering a pharmaceutical composition for cancer treatment or such an ADC to a patient.
[0002] Antibody-drug conjugates (ADCs) are a therapeutic strategy that combines the target specificity of monoclonal antibodies (mAbs) with the potent anticancer activity of cytotoxic drugs, demonstrating high therapeutic efficacy across various cancer types, including solid tumors and hematological malignancies. Antibodies selectively recognize and bind to antigens overexpressed on the surface of specific cancer cells; the drug linked to these antibodies then enters the cell and induces apoptosis. This approach offers the advantage of minimizing non-specific toxicity to non-target cells, which is commonly observed with conventional chemotherapy drugs. In fact, several ADC products have already been approved and are in clinical use, and dozens of ADC candidates are currently in the clinical trial phase.
[0003] In the composition of an ADC, the linker is a critical component that not only serves to chemically link the antibody and the drug but also determines the drug's in vivo stability and the timing of its release within target cells. Ideally, the linker should remain stable in the bloodstream while selectively degrading within cancer cells or the tumor microenvironment to release the drug. Enzyme-sensitive linkers have been developed as a strategy to achieve this objective, and among them, the beta-glucuronide linker possesses the characteristic of being selectively cleaved by an enzyme called beta-glucuronidase. It has been reported that expression levels of beta-glucuronidase are higher in the tumor microenvironment, necrotic tissue, or within lysosomes compared to normal tissues, and in the presence of this enzyme, the beta-glucuronide linker can efficiently release the drug. Therefore, beta-glucuronide linkers are utilized as a useful means to enable selective release within tumor cells while maintaining the blood stability of the drug, and are particularly suitable for the treatment of cancer, which has a clear target, unlike autoimmune or infectious diseases.
[0004] To design an effective antibody-drug conjugate, various characteristics such as stable drug delivery, selective release, maintenance of antibody immunological activity, and optimization of blood half-life must be considered, and there is a need for an improved linker that meets these functional requirements.
[0005] Existing ADC platforms are known to frequently exhibit issues such as reduced in vivo pharmacokinetic stability, non-specific tissue accumulation, low solubility, and aggregation as the drug-to-antibody ratio (DAR) increases. These problems are generally attributed to hydrophobic drugs or linker structures, which can impair therapeutic efficacy by inducing insolubility and non-specific binding in the blood. Specifically, hydrophobicity reduces the solubility of ADCs in aqueous solutions, which can lead to problems such as aggregation or precipitation during manufacturing and formulation processes. Furthermore, increased hydrophobicity promotes interactions with non-specific serum proteins, potentially leading to reduced half-life in the body and a higher risk of off-target distribution. Since these issues can ultimately result in reduced therapeutic efficacy and increased side effects, appropriate control of hydrophobicity has become a critical technical challenge in ADC development.
[0006] Polyethylene glycol (PEG) is a polymer with excellent hydrophilicity, biocompatibility, and chemical versatility. When incorporated into drug conjugates, it is known to contribute to improved water solubility and increased in vivo stability. In particular, the stealth properties of PEG in vivo reduce clearance by proteolytic enzymes or the immune system, thereby extending the blood half-life. Due to these characteristics, PEG is considered the gold standard for conferring hydrophilicity in various biopharmaceuticals and drug delivery systems, and strategies involving the incorporation of PEG chains into linkers or drug structures are still commonly utilized in various ADC platforms. However, some drawbacks have been reported regarding PEG, such as the potential for immunogenicity upon repeated administration or limitations in biodegradability, leading to an increasing need for alternative linkers.
[0007] The present invention relates to an ADC effective for cancer treatment comprising a beta-glucuronide-linker. The present invention aims to provide an ADC with enhanced physical properties required for an ADC and improved cancer treatment efficacy. Specifically, the present invention aims to provide an ADC that is recognized by beta-glucuronidase and easily hydrolyzed, yet remains stable in plasma and has excellent hydrophilicity, resulting in low side effects and improved therapeutic efficacy.
[0008] The present invention relates to an ADC comprising a beta-glucuronide linker that can be selectively cleaved by beta-glucuronidase, wherein the ADC comprises a beta-glucuronide unit containing a sugar residue, a stretcher unit (L) connected to an antibody, and a self-sacrificing spacer unit (Y) connected to a drug. According to a first aspect of the present invention, the ADC according to the present invention does not contain PEG. Surprisingly, the inventors of the present invention discovered that a beta-glucuronide linker containing PEG may be less hydrophilic than one not containing PEG, and further confirmed that when PEG is not included, the cancer treatment efficacy is superior compared to a corresponding configuration containing PEG. A second aspect of the present invention is to use a specific chemical structure as a stretcher unit connected to the beta-glucuronide unit. It has been confirmed that the ADC structure according to the present invention has improved cancer treatment efficacy compared to a conventionally known ADC.
[0009] The numbered items below exemplify some of the embodiments described in this specification.
[0010] 1. An antibody-drug conjugate comprising the following Chemical Formula 1 or Chemical Formula 2, characterized by comprising a beta-glucuronide-linker and not comprising polyethylene glycol:
[0011]
[0012]
[0013] Among the above formulas,
[0014] Su stands for sugar moiety, and
[0015] The L residue is a stretcher unit that is directly or indirectly linked to an antibody, and
[0016] n and m are integers of 0 or 1, respectively; if n is 0, m is 1, and if n is 1, m is 0, and
[0017] The Y residue is a self-immolative spacer unit and is directly or indirectly connected to residues derived from the drug.
[0018] 2. An antibody-drug conjugate in which, in the first embodiment, the L residue has the following chemical formula 3.
[0019] <Chemical Formula 3>
[0020] -R 1 -CONR 2 -R 3 -X- or -R 1 - NR 2 CO-R 3 -X-
[0021] Among the above formulas, R 1 and R 3 are independently, -C1-C 10 Alkylene-, -C1-C 10 alkenylene-, -C3-C8 carbocyclo-, -arylene-, -C1-C 10 Alkylene-arylene-, -C1-C 10 Alkenylene-arylene-, -arylene-C1-C 10 Alkylene-, -arylene-C1-C 10 alkenylene-, -C1-C 10 Alkylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkenylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-arylene-C1-C 10 alkenylene-, -C1-C 10 Alkenylene-arylene-C1-C 10 alkenylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-, -C1-C 10 Alkenylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -(C3-C8 carbocyclo) -C1-C 10 alkenylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)- C1-C 10 Alkylene-, - C1-C 10Alkenylene-( C3-C8 carbocyclo)- C1-C 10 Alkylene-, - C1-C 10 Alkylene-(C3-C8 carbocyclo)-C1-C 10 Alkenylene-, - C1-C 10 Alkenylene-( C3-C8 carbocyclo)- C1-C 10 Alkenylene-, - C3-C8 heterocyclo-, - C1-C 10 Alkylene-(C3-C8 heterocyclo)-, -C1-C10 alkenylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)- C1-C 10 Alkylene-, -( C3-C8 heterocyclo)- C1-C 10 Alkenylene-, - C1-C 10 Alkylene-(C3-C8 heterocyclo)-C1-C 10 Alkylene-, - C1-C 10 Alkenylene-( C3-C8 heterocyclo)- C1-C 10 Alkylene-, - C1-C 10 Alkylene-(C3-C8 heterocyclo)-C1-C 10 Alkenylene-, - C1-C 10 Alkenylene-( C3-C8 heterocyclo)- C1-C 10 Selected from the group consisting of alkenylenes,
[0022] R 2 is H or a substitutable C 1-6 It is alkyl, and
[0023] X does not exist, or NR 2 CO or CONR 2 lim.
[0024] 3. An antibody-drug conjugate in which, in the first or second embodiment, the sugar residue has the following chemical formula.
[0025]
[0026] 4. In the second or third embodiment, n is 1, m is 0, and X is NR 2 CO antibody-drug conjugate.
[0027] 5. An antibody-drug conjugate in any one of the first to fourth embodiments, wherein the L residue comprises maleimide or a ring-opened hydrolyzed maleimide derivative or a divalent group derived therefrom.
[0028] 6. An antibody-drug conjugate comprising the following chemical formula in any one of the first to fifth embodiments.
[0029]
[0030] (In the above formula, the maleimide residue may be ring-opened and connected to the antibody)
[0031] 7. An antibody-drug conjugate in any one of the first to sixth embodiments, wherein the antibody specifically binds to a protein expressed on a tumor cell, or is an antibody or its antigen-binding fragment.
[0032] 8. An antibody-drug conjugate in which the protein expressed on the tumor cell is ROBO1 or HER2 in the seventh embodiment.
[0033] 9. An antibody-drug conjugate in any one of the first to seventh embodiments, wherein the drug is a cytotoxic compound or an immunomodulatory compound.
[0034] 10. An antibody-drug conjugate in any one of the first to seventh embodiments, wherein the drug is selected from the group consisting of a carboxyl-containing drug, a thiol-containing drug, an amino-containing drug, and a hydroxyl-containing drug.
[0035] 11. An antibody-drug conjugate in any one of the first to seventh embodiments, wherein the drug is selected from the group consisting of amanitin, duocamycin, orristatin, orristatin F (AF), monomethyl orristatin F (MMAF), metansine, methansine (DM1), ravtansine (DM4), tubulaisine, calikiamycin, camptothecin, SN-38, exatecan, Maaa-1181a, taxol, daunomycin, vinblastine, doxorubicin, methotrexate, pyrrolobenzodiazepine (PBD) and its dimers, indylinobenzodiazepine (IBD) and its dimers, or radioisotopes thereof and / or pharmaceutically acceptable salts.
[0036] 12. An antibody-drug conjugate in any one of the 9th to 11th embodiments, wherein the drug is exatecan or a derivative thereof.
[0037] 13. A pharmaceutical composition for treating cancer comprising an antibody-drug conjugate described in any one of the first to twelfth embodiments.
[0038] 14. A method for treating cancer comprising administering an antibody-drug conjugate described in any one of the first to twelfth embodiments to a patient requiring treatment for cancer.
[0039] 15. An antibody-drug conjugate comprising the following Formula 1 or Formula 2 containing a beta-glucuronide-linker:
[0040] <Chemical Formula 1>
[0041]
[0042] <Chemical Formula 2>
[0043]
[0044] Among the above formulas,
[0045] Su stands for sugar moiety, and
[0046] The L residue has the following chemical formula 4 and is a stretcher unit linked directly or indirectly to an antibody, and
[0047] <Chemical Formula 4>
[0048] -R 4 -CONR 5 -R 6 -X- or -R 4 - NR 5 CO-R 6 -X-
[0049] (Among the above formulas, R 4 and R 6 are independently, -C1-C 10 Alkylene-, -C3-C8 carbocyclo-, -arylene-, -C1-C 10 Alkylene-arylene-, -arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C3-C8 heterocyclo-, -C1-C 10 Alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C 10 Alkylene- and -C1-C 10 Alkylene-(C3-C8 heterocyclo)-C1-C 10 Selected from the group consisting of alkylene-, and one or more of the carbon atoms of the alkylene are NR 5 , can be substituted with O or CO, and R 5 is H or a substitutable C 1-6 (Alkaline)
[0050] X is NR 5 It is CO, and,
[0051] n and m are integers of 0 or 1, respectively; if n is 0, m is 1, and if n is 1, m is 0, and
[0052] The Y residue is a self-immolative spacer unit and is directly or indirectly connected to residues derived from the drug.
[0053] The matters described in embodiments 3 to 14 above apply equally to the present embodiment including formula 4, unless there is a technical contradiction.
[0054] 16. An antibody-drug conjugate in which, in the 15th embodiment, the sugar residue has the following chemical formula.
[0055] <Chemical Formula 5>
[0056]
[0057] 17. An antibody-drug conjugate in the 15th or 16th embodiment, wherein n is 1 and m is 0.
[0058] 18. An antibody-drug conjugate in any one of the 15th to 17th embodiments, wherein the L residue comprises maleimide or a ring-opened hydrolyzed maleimide derivative or a divalent group derived therefrom.
[0059] 19. An antibody-drug conjugate comprising the following chemical formula in any one of the 15th to 18th embodiments.
[0060] <Chemical Formula 6>
[0061]
[0062] (In the above formula, the maleimide residue may be ring-opened and connected to the antibody)
[0063] 20. An antibody-drug conjugate in any one of the 15th to 19th embodiments, wherein the antibody specifically binds to a protein expressed on a tumor cell, or is an antibody or its antigen-binding fragment.
[0064] 21. An antibody-drug conjugate in which the protein expressed on the tumor cell is ROBO1 or HER2 in the 20th embodiment.
[0065] 22. An antibody-drug conjugate in any one of the 15th to 19th embodiments, wherein the drug is a cytotoxic compound or an immunomodulatory compound.
[0066] 23. An antibody-drug conjugate in any one of the 15th to 19th embodiments, wherein the drug is selected from the group consisting of a carboxyl-containing drug, a thiol-containing drug, an amino-containing drug, and a hydroxyl-containing drug.
[0067] 24. An antibody-drug conjugate in any one of embodiments 15 to 19, wherein the drug is selected from the group consisting of amanitin, duocamycin, orristatin, orristatin F (AF), monomethyl orristatin F (MMAF), metansine, metansine (DM1), labtansine (DM4), tubulaisine, calikiamycin, camptothecin, SN-38, exatecan, Maaa-1181a, taxol, daunomycin, vinblastine, doxorubicin, methotrexate, pyrrolobenzodiazepine (PBD) and its dimer, indylinobenzodiazepine (IBD) and its dimer, or their radioisotopes and / or pharmaceutically acceptable salts.
[0068] 25. An antibody-drug conjugate in which the drug is exatecan or a derivative thereof, in any one of the 22nd to 24th embodiments.
[0069] 26. A pharmaceutical composition for treating cancer comprising an antibody-drug conjugate described in any one of the 15th to 25th embodiments.
[0070] 27. A method for treating cancer comprising administering an antibody-drug conjugate described in any one of the 15th to 25th embodiments to a patient requiring treatment for cancer.
[0071] The ADC according to the present invention comprises a beta-glucuronide linker that is selectively cleaved by beta-glucuronidase, thereby enabling effective drug release in the tumor microenvironment. In addition, it is stable in plasma and has excellent hydrophilicity, allowing it to provide improved therapeutic efficacy with low side effects. The ADC according to the present invention also has the advantages of a simple manufacturing process and a low likelihood of inducing adverse chemical or immune reactions.
[0072] Figures 1 and 2 show the results of size exclusion high-performance liquid chromatography (SEC-HPLC) and liquid chromatography / mass spectrometry (LC-MS) analysis of ADC1. The left side shows the SEC-HPLC chromatogram (monomer purity: 98.44%) and peak area data, and the right side shows the TIC chromatogram, UV 280 nm chromatogram, and deconvolution mass spectrum (MS-DAR: 7.91) for the light chain (LC) and heavy chain (HC).
[0073] Figures 3 and 4 show the SEC-HPLC and LC-MS analysis results of ADC2. The left side shows the SEC-HPLC chromatogram (monomer purity: 98.04%) and peak area data, and the right side shows the TIC chromatogram, UV 280 nm chromatogram, and deconvolution mass spectra (MS-DAR: 7.87) for the light chain (LC) and heavy chain (HC).
[0074] Figures 5 and 6 show the SEC-HPLC and LC-MS analysis results of ADC3. The left side shows the SEC-HPLC chromatogram (monomer purity: 97.99%) and peak area data, and the right side shows the TIC chromatogram, UV 280 nm chromatogram, and deconvolution mass spectra (MS-DAR: 7.86) for the light chain (LC) and heavy chain (HC).
[0075] Figures 7 and 8 show the SEC-HPLC and LC-MS analysis results of ADC4. The left side shows the SEC-HPLC chromatogram (monomer purity: 98.93%) and peak area data, and the right side shows the TIC chromatogram, UV 280 nm chromatogram, and deconvolution mass spectra (MS-DAR: 7.90) for the light chain (LC) and heavy chain (HC).
[0076] Figures 9 and 10 show the SEC-HPLC and LC-MS analysis results of ADC5. The left side shows the SEC-HPLC chromatogram (monomer purity: 98.09%) and peak area data, and the right side shows the TIC chromatogram, UV 280 nm chromatogram, and deconvolution mass spectra (MS-DAR: 8.02) for the light chain (LC) and heavy chain (HC).
[0077] Figures 11 and 12 show the SEC-HPLC and LC-MS analysis results of ADC6. The left side shows the SEC-HPLC chromatogram (monomer purity: 99.69%) and peak area data, and the right side shows the TIC chromatogram, UV 280 nm chromatogram, and deconvolution mass spectrum (MS-DAR: 7.91) for the light chain (LC) and heavy chain (HC).
[0078] Figures 13 and 14 show the SEC-HPLC and LC-MS analysis results of ADC8. The left side shows the SEC-HPLC chromatogram (monomer purity: 99.79%) and peak area data, and the right side shows the TIC chromatogram, UV 280 nm chromatogram, and deconvolution mass spectra (MS-DAR: 8.07) for the light chain (LC) and heavy chain (HC).
[0079] Figures 15 and 16 show the SEC-HPLC and LC-MS analysis results of ADC9. The left side shows the SEC-HPLC chromatogram (monomer purity: 99.32%) and peak area data, and the right side shows the TIC chromatogram, UV 280 nm chromatogram, and deconvolution mass spectra (MS-DAR: 8.00) for the light chain (LC) and heavy chain (HC).
[0080] Figure 17 shows the results of hydrophobic interaction chromatography (HIC) analysis of ADC1 to ADC6. Ab1 is a naked antibody not conjugated with a drug or linker. A shorter elution time indicates higher hydrophilicity.
[0081] Figure 18 shows the results of hydrophobic interaction chromatography (HIC) analysis of an ADC to which the beta-glucuronide linker of the present invention is applied to a trastuzumab antibody. The HIC chromatograms of ADC9 (TRA-Step2-mBG-Exa) without PEG, ADC8 (TRA-Step2-PEG8-mBG-Exa) containing PEG, and the naked antibody (TRA-Step2 mAb) are shown for comparison.
[0082] Figures 19 to 21 show the results of the freeze-thaw stability test of ADC7 as analyzed by SEC-HPLC. SEC-HPLC chromatograms and peak area data for monomer (Main%), high molecular weight aggregate (HMW%), and low molecular weight fragment (LMW%) are shown after 1, 3, and 5 freeze-thaw treatments.
[0083] Figures 22 to 24 show the results of the freeze-thaw stability test of ADC7 as analyzed by hydrophobic interaction chromatography (HIC). The HIC chromatograms after 1, 3, and 5 freeze-thaw treatments are compared.
[0084] Figure 25 shows the results of the serum stability test of ADC7. It shows the changes in concentrations of total antibody, ADC, and free payload over time when cultured in mouse serum, monkey serum, and human serum for up to 168 hours (7 days), respectively.
[0085] Figure 26 shows the change in tumor volume (Mean Tumor Volume ± SEM) and the change in mouse body weight (Mean Body Weight ± SEM) over time when ADC4 (Ab1-PSAR10-BG-Exa) and ADC6 (Ab1-mBG-Exa) were intravenously administered at a dose of 5 mg / kg to mice with tumors derived from the NCI-H1048 cell line.
[0086] Figure 27 shows the change in tumor volume (Mean Tumor Volume ± SEM) and the change in mouse body weight (Mean Body Weight ± SEM) over time when ADC5 (Ab1-BG-Exa) and ADC6 (Ab1-mBG-Exa) were intravenously administered at a dose of 5 mg / kg to mice with tumors derived from the NCI-H1048 cell line.
[0087] Figure 28 shows the change in tumor volume (Mean Tumor Volume ± SEM) and the change in mouse body weight (Mean Body Weight ± SEM) over time when Vehicle (PBS), ADC5 (Ab1-BG-Exa), and ADC6 (Ab1-mBG-Exa) were intravenously administered at a dose of 2.5 mg / kg to mice with tumors derived from the NCI-H1048 cell line.
[0088] Figure 29 shows the tumor growth inhibitory efficacy of JIMT-1, a human breast cancer (BC) cell line expressing HER2, in a xenograft tumor model.
[0089] Unless otherwise specifically defined, the technical and scientific terms used in this specification have the meaning generally understood by those skilled in the art to which the present invention pertains.
[0090] The embodiments described in this specification and the configurations illustrated in the drawings are merely specific examples to aid in understanding the invention and do not limit the technical scope of the invention. At the time of filing this application, various modifications, equivalents, and applications performing substantially the same functions are possible, and a person skilled in the art will understand that such modifications and applications are also included within the scope of the invention.
[0091] The embodiments, features, components, and technical means described herein may be implemented independently or in any combination, unless otherwise explicitly stated to be exclusive or mutually excluded. In particular, technical features described in different paragraphs, items, or embodiments herein may be combined or optionally combined to the extent that there is no technical contradiction, as understood by a person skilled in the art. Such combinations should be understood to be included within the technical spirit and scope of the invention.
[0092] Accordingly, even if a component or feature described in a specific embodiment or paragraph is not explicitly described together with another embodiment or paragraph, it should be interpreted as being directly and clearly derivable from the disclosure of the present invention where it is recognized as technically reasonable by a person skilled in the art.
[0093] definition
[0094] Expressions used in the singular form in this specification are used to include the plural unless the context clearly indicates otherwise. Additionally, the expression “or” is interpreted to include the meaning of “and / or” unless otherwise specified in the context.
[0095] As used herein, the term “comprising” should be understood as an open expression that essentially includes the described components, components, steps, etc., unless specifically stated otherwise, without excluding the existence of additional components, components, steps, etc. Accordingly, the term “comprising” is interpreted as a concept that includes the more restrictive “consisting of” or “consisting essentially of.”
[0096] As used herein, the term "antibody-drug conjugate (ADC)" refers to a conjugate in which a drug (or payload) having cytotoxic or other desired properties is covalently linked to an antibody (or a variant thereof) that specifically recognizes a disease-related antigen. Generally, an ADC consists of a target antibody, a linker, and a drug. The antibody recognizes a specific antigen, such as a tumor cell, to enable targeted delivery of the drug; the linker controls stability in the body and drug release; and the drug is delivered into the cell to induce therapeutic effects such as apoptosis.
[0097] In this specification, "linker" refers to a structural moiety that covalently links an antibody or antigen-binding fragment with a drug-derived residue. The linker can enable the release of the drug by selectively cleaving or degrading within the cell or tumor microenvironment while remaining relatively stable under physiological conditions.
[0098] In some embodiments, the linker may include a beta-glucuronide structure containing a sugar residue and may include a link that can be cleaved by beta-glucuronidase. Accordingly, the linker may be configured to release a drug-derived residue through a self-sacrificial spacer after enzymatic cleavage.
[0099] The above linker may include a stretcher unit, a sugar residue, and an auto-sacrificial spacer unit, wherein the stretcher unit is connected to an antibody and the auto-sacrificial spacer unit is connected to a drug.
[0100] Beta-glucuronide is a metabolite produced in the liver and kidneys by a group of enzymes known as UDP-glucuronosyltransferases. These transferases are involved in metabolic conversion processes to remove foreign substances from the body, and glucuronidation significantly increases the solubility of substrate compounds, facilitating excretion through the kidneys.
[0101] Beta-glucuronidase is a UDP-glucuronosyltransferase present in the lysosomes of almost all human tissues. It catalyzes the hydrolysis of glycosidic bonds of beta-structured glucurons and is reported to have broad substrate specificity. This enzyme exhibits the highest activity under acidic conditions (e.g., within lysosomes, pH ~4.5–5.0) and decreases to approximately 10% at neutral pH (e.g., blood, pH ~7.4). Although this enzyme is widely present, it is primarily isolated within lysosomes in normal tissues, resulting in minimal immunohistochemical staining results in the extracellular space. Unlike normal tissues, high levels of beta-glucuronidase activity are observed in the interstitial space of necrotic tumor tissues. This pH-dependent difference in activity serves as the basis for the ADC of the present invention to remain stable in the blood while selectively releasing the drug into the tumor microenvironment or intracellular lysosomes.
[0102] As used herein, “beta-glucuronide linker” means a linker comprising a site that can be cleaved by the beta-glucuronidase enzyme, for example, a beta-glycosidic bond.
[0103] In the present invention, the “beta-glucuronide linker” is characterized by having a structure in which a sugar residue and a self-sacrificial structure are connected through a beta-glycosidic bond, which is the same as Chemical Formula 1 or 2.
[0104] <Chemical Formula 1>
[0105]
[0106] <Chemical Formula 2>
[0107]
[0108] As used herein, the term “self-immolative structure” refers to a molecular structure designed such that a series of chain reactions of degradation proceeds spontaneously following an initial degradation reaction induced by a specific biochemical or chemical stimulus, ultimately releasing an active compound (e.g., a drug or reporter substance). Such a structure generally consists of a trigger site, a self-immolative spacer, and an active substance (payload). When the trigger site is cleaved by enzymatic action or reduction / oxidation conditions, the spacer undergoes a self-degradation reaction to release the active substance. P-aminobenzyl, p-hydroxybenzyl, or carbonate / carbamate-based structures are widely used as self-immolative spacers, and those skilled in the art are well aware of the structures of self-immolative spacers that can be used in beta-glucuronide-based ADCs.
[0109] In this specification, "stretcher unit" refers to a portion within a linker that is connected to an antibody or antigen-binding fragment and may include a structural moiety connecting the antibody and a sugar residue or a self-sacrificial spacer unit. The stretcher unit may include a reactive group that enables binding with the antibody, and may include a structure capable of reacting, for example, with a cysteine residue or a lysine residue of the antibody. In some embodiments, the stretcher unit may include a maleimide or a structure derived therefrom. Additionally, the stretcher unit may control the length, flexibility, hydrophilicity, and overall physical properties of the linker, thereby contributing to controlling the stability, drug release characteristics, and biological activity of the antibody-drug conjugate.
[0110] In this specification, "maleimide" refers to a compound having an N-substituted or unsubstituted pyrrole-2,5-dione ring structure or a residue thereof. Maleimide can form covalent bonds with thiol groups (-SH) via Michael addition and is utilized as a reactive group connecting the antibody and the linker in the preparation of antibody-drug conjugates.
[0111] In this specification, the phrase “the stretcher unit comprises maleimide or a ring-opened hydrolyzed maleimide derivative” means that the maleimide ring may be ring-opened before or after conjugation with the antibody and exist as a succinimide thioether or in a hydrolyzed form. Specifically, “maleimide or a ring-opened hydrolyzed maleimide derivative, or a divalent group derived therefrom” comprises all of the following: (a) the unreacted maleimide group itself (in a ring-closed form of the maleimide ring); (b) a succinimide thioether structure produced after undergoing a Michael addition reaction with the cysteine thiol group of the antibody, i.e., a form in which a thioether bond is formed without the maleimide ring being ring-opened; (c) a ring-opened form of the succinimide thioether hydrolyzed under physiological conditions or during the manufacturing process, i.e., a structure in which the imide bond is ring-opened to become an amide acid form. (d) A structure in which a valence exists on both sides for connecting via covalent bonding with other chemical units within the linker, i.e., divalent groups derived from (a) to (c) respectively above. Ring-opened maleimides are known to be more stable against deconjugation by retro-Michael reactions.
[0112] As used herein, "polyethylene glycol (PEG)" refers to a linear or branched nonionic hydrophilic polymer composed of repeating units of ethylene oxide. PEG is generally -(CH2CH2O) nIt has a structure, and its physical properties and in vivo behavioral characteristics vary depending on its molecular weight (the size of n). PEG is physiologically inactive, has high solubility in water, and can be introduced into proteins or drug molecules via covalent or non-covalent bonds, so it is utilized for purposes such as increasing drug solubility, extending blood half-life, evading immune responses, and improving drug stability.
[0113] In this specification, the expression “not containing PEG” means that no polymer chain composed of the ethylene oxide repeating unit is present in any part of the antibody, linker, and drug of the ADC. However, a simple ethylene linker at the level of a single ethylene glycol monomer is not considered to be PEG.
[0114] As used herein, the “sugar residue (Su)” may be a cyclic hexose such as pyranose or a cyclic pentose such as furanose. The sugar residue typically has a beta-D stereoconfiguration. In some embodiments, the sugar residue may be an unsubstituted cyclic hexose or a cyclic pentose. In other embodiments, the sugar residue may be a substituted beta-D-glucuronide, wherein the substituent may be one or more of hydroxyl, halogen, sulfur, nitrogen, or lower alkyl.
[0115] As used herein, the term "antibody" refers to a protein of the immunoglobulin family that includes a binding site capable of binding to a specific antigen, and includes all forms that are naturally occurring or produced by recombinant technology. This includes full-length antibodies (e.g., IgG, IgA, IgM, IgD, IgE), as well as all fragments that retain the functional characteristics of the antibody (Fab, Fab', F(ab')2, scFv, etc.) and variants derived from humanized, chimeric, fully human, or synthetic libraries. Additionally, it includes variants or fusion protein forms that are modified to improve binding affinity, stability, half-life, heterogeneous function, etc., while maintaining the ability to specifically bind to an antigen.
[0116] As used herein, the term "antigen-binding fragment" refers to a portion of a protein that is part of the whole antibody but retains the ability to bind to an antigen.
[0117] The above antibody or antigen-binding fragment may include a full-length antibody, Fab, Fab', F(ab')2, scFv, etc.
[0118] In this specification, "payload" or "drug-derived residue" refers to a bioactive substance that is linked to an antibody or antigen-binding fragment via a linker in an antibody-drug conjugate. The payload may include a compound capable of inhibiting cell proliferation or inducing apoptosis. In other embodiments, the payload may include an immunomodulatory compound that regulates an immune response or a compound that induces the degradation of a target protein.
[0119] In this specification, "DAR (drug-to-antibody ratio)" refers to the average number of drug-derived residues bound to a single antibody or antigen-binding fragment molecule. The DAR may affect the physical properties, stability, and biological activity of the antibody-drug conjugate, and the drug delivery efficiency and therapeutic effect can be optimized through the appropriate adjustment of the DAR. In the present invention, the DAR may preferably be in the range of about 2 to about 10, and more preferably about 4 to about 8, but is not limited thereto.
[0120] As used herein, the term "tumor microenvironment (TME)" refers to the cellular environment surrounding tumor cells, meaning a complex biological environment that includes, in addition to cancer cells, immune cells, vascular cells, stromal cells, the extracellular matrix, and various cytokines and enzymes. Unlike normal tissues, the tumor microenvironment is characterized by low pH, high beta-glucuronidase activity, and hypoxic conditions, and these characteristics enable the selective cleavage of the beta-glucuronide linker in the ADC of the present invention.
[0121] As used herein, "ROBO1" refers to Roundabout Guidance Receptor 1, a transmembrane protein involved in cell migration and neural guidance as a receptor for slit ligands. ROBO1 is known to be overexpressed in some solid tumors, particularly small cell lung cancer (SCLC). In the present invention, "anti-ROBO1 antibody" refers to an antibody that specifically binds to the ROBO1 protein or its epitope and includes an antigen-binding fragment thereof. The amino acid sequence of human ROBO1 includes, for example, the sequence described in UniProtKB accession number Q9Y6N7 or NCBI RefSeq accession number NP_002932.1.
[0122] As used herein, "exatecan" is a topoisomerase I inhibitor and is a camptothecin derivative, and its chemical name is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione. Exatecan exhibits potent cytotoxicity. In "exatecan or its derivatives," "its derivatives" means compounds based on the chemical structure of exatecan but with one or more substituent modifications, functional group introductions, or structural modifications, which possess topoisomerase I inhibitory activity substantially similar to that of exatecan.
[0123] In this specification, the expression “directly or indirectly connected” includes cases where two chemical sites are (i) directly connected to each other via covalent bonds, or (ii) connected via one or more intermediate chemical structures (e.g., linkers, spacers, protecting groups, or functional residues). That is, it includes not only forms in which the Y residue and the drug-derived residue are connected solely by separate covalent bonds, but also structures indirectly connected through chemical groups such as carbamates, carbonates, ureas, esters, or amines. These connection methods may be selected in various ways depending on the purpose, such as drug release mechanisms, control of reactivity, or ensuring in vivo stability. The connection between the L residue and the antibody is also included within the scope of the present invention not only in cases where a direct covalent bond is formed with the antibody's amino acid residue (e.g., lysine or cysteine), but also indirect connection structures involving functional groups such as maleimide, hydrazine, azide, or alkyne, or PEG, polysarcosine, or other spacer units. Such connection types can serve as important factors in controlling the selectivity, stability, and in vivo drug delivery efficiency of the binding.
[0124] As used herein, the term “specifically binding” means binding that has significantly higher binding affinity and selectivity than non-specific interactions with respect to a binding target (e.g., antigen, receptor, ligand, etc.). Generally, this includes, but is not limited to, cases where the dissociation constant (KD) for the target antigen is at least about 10 times, preferably at least about 100 times, and more preferably at least about 1,000 times lower than the KD for the non-target substance. Such specificity can be determined by known analytical methods that can be easily performed by a person skilled in the art (e.g., enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), biolayer interferometer (BLI), fluorescence or radiolabeled binding assay, etc.). “Specific binding” does not require the complete absence of cross-reactivity, and may be interpreted as satisfying this requirement if preferential binding to the target antigen occurs.
[0125] As used herein, the term "alkylene" refers to a radical group having a chain-like structure composed of saturated hydrocarbons, with both ends capable of bonding. The alkylene may include straight-chain, branched, or combinations thereof, and may have various carbon arrangements within its structure. Non-limiting examples include methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), isopropylene, butylene, pentylene, hexylene, etc. Additionally, the alkylene may have various bonding sites when bonding with other groups and may include structurally modified forms depending on the bonding method. The alkylene may optionally be substituted with one or more substituents and may include forms in which physical and chemical properties are altered upon the introduction of the substituents.
[0126] As used herein, the term "alkenylene" refers to an unsaturated hydrocarbon chain structure containing one or more double bonds, meaning a divalent group in which both ends are bondable. The alkenylene may include a straight-chain, branched, or a combination thereof, and may include various structural isomers depending on the position and number of double bonds. Additionally, the alkenylene may include geometric isomers (e.g., cis / trans forms), and all such isomers are included within the scope of this specification. The alkenylene may optionally be substituted with one or more substituents.
[0127] As used herein, the term "carbocyclo" refers to a group having a ring structure composed solely of carbon atoms. The carbocyclo may include a saturated ring, a partially unsaturated ring, or an aromatic ring, and may include a monocyclic or polycyclic structure. Additionally, the carbocyclo may include a fused ring, a condensed ring, or a spiro ring structure, and may include various ring arrangements and bonding forms. The carbocyclo may optionally be substituted with one or more substituents, and is not limited to the substitution position or substitution form.
[0128] As used herein, the term "arylene" refers to a diaromatic hydrocarbon group comprising one or more aromatic rings. The arylene may comprise a monocyclic or polycyclic aromatic structure and may comprise aromatic rings bonded together or condensed aromatic systems. Additionally, the arylene may have various bonding positions and may comprise different structural forms depending on the bonding positions. The arylene may optionally be substituted with one or more substituents.
[0129] As used herein, the term "heterocyclo" refers to a group having a ring structure and containing one or more heteroatoms. The heteroatoms may include nitrogen (N), oxygen (O), sulfur (S), etc., and may also include one or more different heteroatoms. The heterocyclo may include a saturated ring, a partially saturated ring, or an aromatic ring, and may include a monocyclic or polycyclic structure. Additionally, the heterocyclo may include a fused ring, a condensed ring, or a spiro structure, and may include various ring arrangements. The heterocyclo may optionally be substituted with one or more substituents, and is not limited to the substitution position and form.
[0130] All groups defined in this specification may include straight-chain, branched, cyclic, or combinations thereof, unless otherwise specified. Additionally, the groups may optionally be substituted with one or more substituents, and the type, number, and position of the substituents are not particularly limited. The bonding position of each group may be any one of the possible bonding positions of the group, and may include all structurally possible isomer forms.
[0131] In this specification, "substitutable C" 1-6 Alkyl (substitutable C 1-6 "alkyl" refers to a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, wherein one or more hydrogen atoms can be replaced by substituents. In other words, "substitutable" means that substitution is permitted and does not require that the group be substituted. Unsubstituted C 1-6 Alkyls (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, etc.) are also "substituteable C 1-6 It is included in the range of "alkyl".
[0132] In this specification, the term “substituted” means a state in which one or more hydrogen atoms of the group are substituted with other atoms or groups. The term “optionally substituted” means a state in which the group is not substituted or is substituted with one or more substituents. The type, number, and substitution position of the substituents are not particularly limited and may be one or more within a structurally possible range.
[0133] In this specification, "ring-opening hydrolysis" refers to a reaction in which a compound having a cyclic structure undergoes a structural transformation as the ring opens upon reaction with water. Such ring-opening hydrolysis may occur in various cyclic compounds, and the ring-opened structure resulting from hydrolysis may exhibit different chemical properties or reactivity compared to the cyclic structure. In some embodiments, such ring-opening hydrolysis may occur in the linker or a part thereof, thereby altering the stability or physical properties of the bond.
[0134] The term “complex” as used in this specification refers to a structure formed by two or more molecules (e.g., peptides, proteins, antibodies, antigen-binding fragments, nucleic acids, ligands, or receptors, etc.) being joined together by covalent or non-covalent interactions, and such joining may be direct or indirect through mediating molecules.
[0135] In this specification, "cytotoxic compound" means a physiologically active substance that inhibits cell proliferation or induces apoptosis. The cytotoxic compound may affect cell survival by inhibiting the function of DNA, RNA, or proteins or by inhibiting the progression of the cell cycle. In some embodiments, the cytotoxic compound may include a topoisomerase inhibitor, a microtubule inhibitor, or a compound that induces DNA damage. In one embodiment, the cytotoxic compound may include a topoisomerase I inhibitor, for example, exatecan or a derivative thereof.
[0136] In this specification, "immunomodulatory compound" refers to a physiologically active substance that alters an immune response by regulating the activity, proliferation, or function of immune cells. The immunomodulatory compound may enhance or inhibit an immune response and may include, for example, cytokines, immune checkpoint modulators, or small molecule compounds that regulate the activity of immune cells. In some embodiments, the immunomodulatory compound may contribute to an antitumor effect by regulating the immune response in the tumor microenvironment.
[0137] In this specification, "degradation compound" refers to a physiologically active substance that inhibits or eliminates the function of a target protein by inducing its degradation. The degradation compound may promote the degradation of the target protein using an intracellular protein degradation system and may act, for example, through the ubiquitin-proteasome pathway or the lysosome pathway. In some embodiments, the degradation compound may include a dual-functional compound capable of simultaneously binding to the target protein and the protein mediating the degradation mechanism.
[0138] In this specification, "carboxyl-containing drug" refers to a drug-derived residue comprising one or more carboxylic acid groups (-COOH) or derivatives thereof within the molecule. The carboxylic acid groups may be utilized in various forms for binding with a linker, for example, to form ester, amide, or carbamate bonds. In some embodiments, the carboxylic acid groups may be converted into an activated form to bind to a linker or an autosacrificial spacer. The carboxyl-containing drug may bind to a linker through the functional groups to form an antibody-drug conjugate.
[0139] In this specification, "thiol-containing drug" refers to a drug-derived residue containing one or more thiol groups (-SH) within the molecule. The thiol groups may act as reactive groups for binding with a linker, for example, by reacting with maleimide to form a covalent bond. In some embodiments, the thiol groups may exist in an activated form or be provided in a converted form to bind with the linker. The thiol-containing drug may bind to the linker through the functional groups to form an antibody-drug conjugate.
[0140] In this specification, "derivative" means a compound in which one or more chemical modifications are introduced while maintaining the basic structure of a reference compound. The chemical modifications may include substitution, addition, bonding, cleavage, or other structural modifications, and may include, for example, substitution of one or more functional groups, alkylation, acylation, halogenation, oxidation, or reduction. In some embodiments, the derivative may be a form in which solubility, stability, cell permeability, or pharmacokinetic properties are controlled while maintaining substantially similar biological activity to the reference compound.
[0141] In this specification, the term “cancer” refers to a group of diseases in which the regulation of cell proliferation is lost and incomplete differentiation and invasiveness increase, forming an abnormal proliferative mass (tumor) within a tissue or systemically. Cancer may include solid tumors and hematologic malignancy. In one embodiment, the cancer may be a cancer expressing ROBO1.
[0142] In this specification, the term “prevention” means any act or measure intended to suppress or delay the occurrence of a specific disease or symptom. Prevention includes preemptive measures taken before the disease manifests, or acts to prevent clinical deterioration or progression even if initial changes in the disease are present, and may be achieved through the biological action or mechanistic effect of the target substance.
[0143] In this specification, the terms “treatment” or “therapy” mean any medical or pharmacological measure intended to alleviate, relieve, stabilize, inhibit the progression of, or substantially improve an existing disease or symptom. This includes the alleviation of symptoms, restoration of tissue function, and inhibition of pathophysiological changes, and the degree of treatment includes both partial and complete improvement.
[0144] As used herein, the term “pharmaceuticalally acceptable carrier” means a substance that enables a pharmaceutical composition containing an active ingredient to be safely administered in vivo and provides physical and chemical stability, solubility, or suitability for administration of the active ingredient. Such a carrier may include water-soluble or water-insoluble media depending on the route of administration and may be selected within a range that does not substantially affect the pharmacological activity of the active ingredient.
[0145] As used herein, the term “pharmaceuticalally acceptable diluent” refers to a substance used to adjust the concentration of an active ingredient or to increase the volume or weight of a formulation, and which serves to improve the ease of administration, quantification, or uniformity of a pharmaceutical composition. The diluent may be selected within a range that is chemically stable with respect to the active ingredient and does not adversely affect the safety and efficacy of the pharmaceutical composition.
[0146] As used herein, the term “pharmaceuticalally acceptable excipient” means an auxiliary component used to improve the stability, release characteristics, bioavailability, or physical properties of an active ingredient during the preparation, storage, or administration of a pharmaceutical composition. Such excipients may include, but are not limited to, stabilizers, buffers, isotonic agents, preservatives, antioxidants, binders, disintegrants, or coating agents, for example.
[0147] In this specification, "pharmaceutically acceptable salt" means a salt derived from a pharmacologically acceptable inorganic acid, organic acid, inorganic base, or organic base, and examples of acid addition salts include hydrochloride, sulfate, nitrate, acetate, trifluoroacetate, maleate, citrate, etc., and examples of base addition salts include, but are not limited to, sodium salt, potassium salt, calcium salt, ammonium salt, etc.
[0148] 1. Linker
[0149] The present invention provides a novel linker applicable to antibody-drug conjugates (ADCs).
[0150] The above linker is a structural moiety that connects an antibody and a drug via a covalent bond, and is configured to maintain stability under physiological conditions while being selectively cleaved or degraded by the intracellular environment, such as enzymatic degradation, thereby enabling the effective release of the drug from the antibody.
[0151] The linker according to the present invention may include a group that can be selectively cleaved by a specific enzyme within the cell, and in one embodiment may have a structure including a beta-glucuronide-based cleavable moiety.
[0152] In one embodiment, the linker according to the present invention is characterized by comprising the following chemical formula 1 or chemical formula 2.
[0153] <Chemical Formula 1>
[0154]
[0155] <Chemical Formula 2>
[0156]
[0157] Among the above formulas, Su represents a sugar moiety. The sugar moiety may include a cyclic hexose or a cyclic pentose, and in one embodiment, may be a glucuronide moiety having a beta configuration. In some embodiments, the sugar moiety may be an unsubstituted beta-D-glucuronide, and in other embodiments, may be a glucuronide derivative comprising one or more substituents. Such a sugar moiety may be connected to an autosacrificial spacer unit via a beta-glycosidic bond.
[0158] In some embodiments of the present invention, the sugar residue (Su) functions as a substrate recognized by beta-glucuronidase to hydrolyze the glycosidic bond. The sugar residue is preferably a pyranose-type hexose having a beta-D stereochemical configuration, and is particularly preferably a beta-D-glucuronide. Beta-D-glucuronide is highly hydrophilic due to the carboxylic acid group at the C6 position, which can contribute to improving the water solubility and physical properties of the entire ADC.
[0159] Chemical formulas 1 and 2 represent two structural regioisomers of a beta-glucuronide linker in which a sugar residue (Su), a stretcher unit (L), and a drug are arranged around a self-sacrificial spacer unit (Y) with a benzene ring as the core scaffold. Chemical formulas 1 and 2 are structural regioisomers of each other, and an ADC containing either one of these satisfies the requirements of the present invention.
[0160] The beta-glucuronide linker according to the present invention may include a beta-glycosidic bond that can be cleaved by beta-glucuronidase. Such enzymatic cleavage may be induced in intracellular organelles such as lysosomes or in the tumor microenvironment, and as a result, the degradation of the self-sacrificial spacer may subsequently proceed, thereby promoting the release of the drug. Accordingly, the linker according to the present invention may be designed to remain relatively stable in the blood while selectively releasing the drug in target cells or tumor-associated environments.
[0161] Although not limited to theory, the drug release mechanism may proceed in the following sequence: (1) the ADC specifically binds to a target antigen (e.g., ROBO1) on the surface of the tumor cell through the antibody portion; (2) the antigen-ADC complex enters the cell through endocytosis; (3) the entered ADC moves to the lysosome, and the beta-glycosidic bond is hydrolyzed by the acidic environment (pH ~4.5~5.0) and high beta-glucuronidase activity within the lysosome; (4) the cleavage of the glycosidic bond activates the self-sacrificial spacer, and a series of spontaneous degradation reactions (e.g., 1,6-elimination reaction) proceed; (5) the active drug is released in a free form through the self-sacrificial reaction; (6) the released drug acts on an intracellular target to induce apoptosis. In addition, some drugs diffuse to adjacent cells after release and can exert a bystander killing effect on surrounding antigen-negative cells.
[0162] In one embodiment, the sugar residue comprises the following chemical formula structure.
[0163] <Chemical Formula 5>
[0164]
[0165] In the above formulas, L represents a stretcher unit. The stretcher unit may be connected directly or indirectly to the antibody. It can control the spacing, orientation, reactivity, and stability between the antibody and the beta-glucuronide unit containing a sugar residue. In some embodiments, the L unit may include a structure capable of directly binding to an amino acid residue of the antibody, for example, a cysteine or lysine residue. In other embodiments, the L unit may be connected indirectly to the antibody through one or more functional linkers.
[0166] The stretcher unit (L) is a divalent chemical structure that connects the antibody and the beta-glucuronide linker, and plays an important role in the physical properties, blood stability, and antibody conjugation specificity of the ADC.
[0167] As a non-limiting example of how a stretcher unit is connected to an antibody, in the maleimide-thiol conjugation method, the maleimide group of the stretcher unit forms a covalent bond with the thiol group of a cysteine residue of the antibody through a Michael addition reaction, and the resulting succinimide thioether bond is stable under physiological conditions and can be converted to a ring-opened form by hydrolysis. In the NHS ester-amino conjugation method, the activated ester group of the stretcher unit can react with the amino group of a lysine residue of the antibody to form an amide bond. Additionally, site-specific conjugation methods using non-natural amino acids or sugar engineering may also be included within the scope of the present invention.
[0168] Maleimide-thiol conjugation proceeds selectively and efficiently under aqueous conditions near neutral pH, and can be advantageous for the production of uniform ADCs due to low reaction byproducts and high reproducibility.
[0169] In one embodiment, the stretcher unit (L) may include a structure represented by the following chemical formula 3:
[0170] <Chemical Formula 3>
[0171] -R 1 -CONR 2 -R 3 -X- or -R 1 -NR 2 CO-R 3 -X-
[0172] Among the above formulas, R 1 and R 3 C1-C each independently 10 Alkylene-, -C1-C 10 alkenylene-, -C3-C8 carbocyclo-, -arylene-, -C1-C 10Alkylene-arylene-, -C1-C 10 Alkenylene-arylene-, -arylene-C1-C 10 Alkylene-, -arylene-C1-C 10 alkenylene-, -C1-C 10 Alkylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkenylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-arylene-C1-C 10 alkenylene-, -C1-C 10 Alkenylene-arylene-C1-C 10 alkenylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-, -C1-C 10 Alkenylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -(C3-C8 carbocyclo)-C1-C 10 alkenylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkenylene-(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-C1-C 10 alkenylene-, -C1-C 10 Alkenylene-(C3-C8 carbocyclo)-C1-C 10 alkenylene-, -C3-C8heterocyclo-, -C1-C 10 Alkylene-(C3-C8 heterocyclo)-, -C1-C 10 Alkenylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C 10 Alkylene-, -(C3-C8 heterocyclo)-C1-C 10 alkenylene-, -C1-C 10 Alkylene-(C3-C8 heterocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkenylene-(C3-C8 heterocyclo)-C1-C 10 Alkylene-, -C1-C 10Alkylene-(C3-C8 heterocyclo)-C1-C 10 alkenylene-, -C1-C 10 Alkenylene-(C3-C8 heterocyclo)-C1-C 10 It may include alkenylene, etc.
[0173] R 2 is H or a substitutable C 1-6 It can be an alkyl.
[0174] Among the above equations, X does not exist or is NR 2 CO or CONR 2 It could be.
[0175] In Chemical Formula 3 described in this specification, R 1 The terminal is a site directly or indirectly connected to an antibody or antigen-binding fragment, and the X-terminal is a site directly or indirectly connected to a linker core containing a beta-glucuronide unit (Su) and a self-sacrificial spacer unit (Y).
[0176] The stretcher unit (L) containing the structure represented by Chemical Formula 3 does not contain polyethylene glycol (PEG).
[0177] In some embodiments, X is NR 2 It could be CO.
[0178] In one embodiment, in Formula 3, R 1 and R 3 are independently - C1-C 10 Alkylene- and, R 2 is H, and X is NR 2 It is CO.
[0179] In one embodiment, in Formula 3, R 1 is -C3-C7alkylene-, and R 3 is -C1-C4alkylene-, and R 2 is H, and X is NR 2 It is CO.
[0180] In one embodiment, in Formula 3, R 1 is -C5alkylene-, and R3 is -C2alkylene-, and R 2 is H, and X is NR 2 It is CO.
[0181] In addition, among the above expressions, n and m may each be integers of 0 or 1, and when n is 0, m is 1, and when n is 1, m is 0.
[0182] In one embodiment, n can be 1 and m can be 0.
[0183] In another embodiment, n is 1 and m is 0, and X is NR 2 It could be CO.
[0184] In one embodiment, the L unit may comprise maleimide, a ring-opened hydrolyzed maleimide derivative, or a divalent group derived therefrom. Such a structure may be useful for reacting with a cysteine residue of an antibody to form a stable bond.
[0185] In some embodiments, the maleimide residue may exist in a ring-opened form after conjugation.
[0186] Among the above formulas, the Y residue represents a self-immolative spacer unit. The Y residue is directly or indirectly connected to a residue derived from a drug.
[0187] The self-sacrificial spacer unit (Y) serves to spontaneously degrade without additional enzymatic action after the cleavage of the beta-glycosidic bond by beta-glucuronidase, thereby releasing the drug. The Y residue is directly or indirectly linked to the drug-derived residue, and an appropriate linkage method may be selected depending on the type of functional group (carboxyl, thiol, amino, hydroxyl) of the drug. In some embodiments, the Y unit may include p-aminobenzyl, p-hydroxybenzyl, carbonate, carbamate, or a similar self-sacrificial structure. In one embodiment, the Y unit includes a p-aminobenzyloxycarbonyl (PABC) structure and may be linked to the drug via a carbamate bond.
[0188] The above PABC self-sacrificial spacer spontaneously degrades through a 1,6-elimination reaction after cleavage of the beta-glycosidic bond by beta-glucuronidase, thereby releasing the drug. The carbamate bond between the Y unit and the drug may be formed with the amino group or hydroxyl group of the drug.
[0189] In one embodiment, the linker according to the present invention may not include a hydrophilic polymer moiety.
[0190] In this specification, "hydrophilic polymer moiety" means a structure comprising polyethylene glycol (PEG) or a similar hydrophilic polymer. In some embodiments, the linker according to the present invention or the ADC comprising it may not contain PEG.
[0191] In this specification, "PSAR" means polysarcosine and is a hydrophilic polypeptide composed of repeating units of N-methylglycine (sarcosine). PSAR is known to be applicable to ADCs for the purpose of enhancing the hydrophilicity of the linker, similar to PEG. In one embodiment, the linker according to the present invention may not include PSAR.
[0192] Conventionally, PEG has been recognized as a useful means for imparting hydrophilicity; however, the inventors have confirmed that in certain structures containing a beta-glucuronide linker, a configuration that does not include PEG can actually exhibit enhanced hydrophilicity or superior therapeutic efficacy. It is understood that the beta-D-glucuronide sugar residue itself provides sufficient hydrophilicity due to the carboxylic acid group at the C6 position and multiple hydroxyl groups, and that this inherent hydrophilicity can contribute to maintaining the physical properties of the ADC even without the introduction of PEG. Accordingly, the present invention can provide a beta-glucuronide-based linker capable of achieving excellent physical properties and biological activity without including PEG.
[0193] In addition, there may be additional benefits obtained by not including PEG: (a) reduced immunogenicity: the formation of anti-PEG antibodies against PEG can adversely affect the pharmacokinetics of the ADC upon repeated administration, and this risk can be reduced by not including PEG; (b) simplified manufacturing process: the step of introducing the PEG chain is unnecessary, reducing the synthesis steps and allowing for more efficient manufacturing of a highly uniform ADC; (c) potential for improved tumor penetration: PEG chains can increase the hydrodynamic size of the ADC, which can hinder penetration into tumor tissue, but the PEG-free structure has a smaller molecular weight, which can improve penetration into the tumor.
[0194] In one embodiment, the linker according to the present invention does not include polyethylene glycol in the stretcher (L) unit.
[0195] In one embodiment, the linker according to the present invention does not include PSAR in the stretcher (L) unit.
[0196] In one embodiment, the linker according to the present invention is characterized in that it does not include an alkenylene group or an alkynylene group in the stretcher (L) unit.
[0197] In this specification, "alkenylene" refers to an unsaturated hydrocarbon chain structure containing one or more double bonds, meaning a radical form of group at both ends capable of bonding. The alkenylene may include a straight-chain, branched, or a combination thereof, and may include various structural forms depending on the position and number of double bonds. Additionally, the alkenylene may include geometric isomers, all of which are included within the scope of this specification. The alkenylene may have different linkage forms depending on the bonding position and may include various structurally possible isomers. Furthermore, the alkenylene may optionally be substituted with one or more substituents, and the type, number, and substitution position of the substituents are not particularly limited.
[0198] In this specification, "alkynylene" refers to an unsaturated hydrocarbon chain structure containing one or more triple bonds, with both ends having a radical form capable of bonding. The alkynylene may include a straight-chain, branched, or a combination thereof, and may include various structural forms depending on the position and number of triple bonds. Additionally, the alkynylene may have different linkage forms depending on the bonding position and may include various structurally possible isomers. The alkynylene may optionally be substituted with one or more substituents, and the type, number, and substitution position of the substituents are not particularly limited.
[0199] In this specification, the expression “does not contain unsaturated bonds” means that carbon-carbon double bonds (C=C) and carbon-carbon triple bonds do not exist within the carbon skeleton of the L residue. On the other hand, amide bonds (-CO-NH-, i.e., C=O) included in the structure of the chemical formula according to the present invention are not subject to this requirement for the exclusion of unsaturated bonds.
[0200] In another embodiment, the L unit may include a structure represented by the following chemical formula 4:
[0201] The embodiments described above regarding Chemical Formula 3 (including the established, n / m conditions and descriptions related to maleimide) apply equally to Chemical Formula 4, unless there is a technical contradiction.
[0202] <Chemical Formula 4>
[0203] -R 4 -CONR 5 -R 6 -X- or -R 4 -NR 5 CO-R 6 -X-
[0204] Among the above formulas, R 4 and R 6 Each independently -C1-C 10 Alkylene-, -C3-C8 carbocyclo-, -arylene-, -C1-C 10 Alkylene-arylene-, -arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C3-C8 heterocyclo-, -C1-C 10 Alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C 10Alkylene- and -C1-C 10 Alkylene-(C3-C8 heterocyclo)-C1-C 10 It may include alkylene-, etc., and one or more of the carbon atoms of the alkylene are NR 5 It can be replaced with , O or CO.
[0205] R 5 is H or a substitutable C 1-6 It can be an alkyl,
[0206] X is NR 5 It could be CO.
[0207] In Chemical Formula 4 described in this specification, R 4 The terminal is a site directly or indirectly connected to an antibody or antigen-binding fragment, and the X-terminal is a site directly or indirectly connected to a linker core containing a beta-glucuronide unit (Su) and a self-sacrificial spacer unit (Y).
[0208] In one embodiment, in Formula 4, R 4 and R 6 -C1-C each independently 10 Alkylene- and, R 5 is H, and X is NR 5 It is CO.
[0209] In one embodiment, in Formula 4, R 4 is -C3-C7alkylene-, and R 6 is -C1-C4alkylene-, and R 5 is H, and X is NR 5 It is CO.
[0210] In one embodiment, in Formula 4, R 4 is -C5alkylene-, and R 6 is -C2alkylene-, and R 5 is H, and X is NR 5 It is CO.
[0211] In some embodiments, n may be 1 and m may be 0.
[0212] In one embodiment, the stretcher unit (L) comprising a structure represented by Formula 4 does not contain polyethylene glycol (PEG).
[0213] In one embodiment, the stretcher unit (L) comprising a structure represented by Chemical Formula 4 does not include PSAR.
[0214] In addition, the stretcher unit (L) comprising the structure represented by Chemical Formula 4 according to the present invention is characterized by not containing unsaturated bonds, such as alkenylene groups or alkynylene groups, within the carbon backbone. By excluding residues containing unsaturated bonds from the stretcher unit in this manner, the possibility of unintended structural deformation due to oxidation, photodegradation, or in vivo enzymatic reactions can be reduced, and it is expected that the chemical stability and blood stability of the ADC can be improved. Furthermore, the absence of unsaturated bonds can contribute to minimizing the possibility of unexpected secondary reactions while maintaining the stereochemical flexibility of the linker structure at a certain level.
[0215] In one embodiment, the linker according to the present invention may include a structure of the following chemical formula.
[0216] <Chemical Formula 6>
[0217]
[0218] In the above formula, the maleimide residue can be directly or indirectly bound to the reactive group of the antibody, and can form a covalent bond, for example, through a Michael addition reaction with the thiol group of the cysteine residue of the antibody. Meanwhile, the -NH terminus can be directly or indirectly bound to the drug, and can be linked to the drug, for example, through an amide bond.
[0219] Adopting a maleimide structure as an antibody linker in the linker according to the present invention and not using residues containing unsaturated bonds (alkenylene groups, alkynylene groups, etc.) in the stretcher unit may provide the following advantages in terms of manufacturing. Maleimide-thiol conjugation proceeds selectively and efficiently under aqueous conditions near neutrality, and the reaction can be completed under mild conditions without additional metal catalysts or high-temperature conditions, which may be advantageous for maintaining the structural integrity of the antibody. Meanwhile, by excluding residues containing unsaturated bonds from the stretcher unit, the possibility of side reactions caused by oxidation or photodegradation during manufacturing and storage can be reduced, which can contribute to the reproducible production of uniform and stable ADCs. Furthermore, the simplification of the linker structure may also be advantageous for reducing synthesis steps and increasing the efficiency of the manufacturing process.
[0220]
[0221] Alternatively, when the linker of the present invention is directly bound to an antibody, the maleimide residue may be ring-opened and connected to the antibody as in Chemical Formula 7.
[0222] 2. ADC
[0223] One aspect of the present invention provides an ADC comprising the linker described above.
[0224] The antibody-drug conjugate (ADC) according to the present invention may comprise an antibody, a linker, and a drug.
[0225] The above antibody can be directly or indirectly linked through the L residue of the linker, and the above drug can be linked through the Y residue of the linker.
[0226] The ADC according to the present invention may include an antibody or an antigen-binding fragment that specifically binds to a protein expressed on a tumor cell.
[0227] The antibody used in the ADC of the present invention is preferably an antibody or an antigen-binding fragment thereof that specifically binds to a protein expressed on tumor cells. Such an antibody is preferably a monoclonal antibody, but is not limited thereto, and may be a polyclonal antibody, a chimeric antibody, a humanized antibody, a fully human antibody, a bispecific antibody, or an antigen-binding fragment thereof (e.g., Fab, F(ab')2, scFv, nanobodies, etc.).
[0228] Non-limiting examples of tumor cell surface proteins to which the antibody binds include, but are not limited to, HER2, HER3, EGFR, VEGFR, FGFR, MET, ROR1, ROR2, BCMA, CD19, CD20, CD22, CD30, CD33, CD38, CD56, CD70, CD79b, CD138, EpCAM, Nectin-4, FOLR1, MSLN, CEACAM5, Trop-2, ROBO1, etc. In one embodiment, the target protein to which the antibody binds may be ROBO1 or HER2.
[0229] The antibody isotype may be IgG1, IgG2, IgG3, IgG4, or a variant thereof, and preferably IgG1. The antibody's constant region (Fc region) may be engineered, such as through amino acid substitution, for pharmacokinetic (PK) optimization, modulation of effector function, or extension of half-life via FcRn binding.
[0230] The technical feature of the present invention lies in the structure of the beta-glucuronide linker itself, in particular the arrangement of the sugar residue (Su), the stretcher unit (L), and the self-sacrificing spacer unit (Y), which is an element independent of the type of antibody to be bound. Therefore, the linker according to the present invention is expected to exhibit equivalent linker function even when combined with various antibodies or antigen-binding fragments. In fact, the inventors observed that the same pattern was reproduced in ADCs using multiple anti-ROBO1 antibodies having different antibody sequences, and furthermore, the same pattern was confirmed in trastuzumab-based ADCs, which are anti-HER2 antibodies. This implies that the linker of the present invention is not limited to specific antibody sequences and can be applied broadly.
[0231] The drug included in the ADC according to the present invention may include a physiologically active substance capable of inhibiting cell proliferation or inducing apoptosis.
[0232] In some embodiments, the drug may be a cytotoxic compound. The cytotoxic compound may affect cell survival by inhibiting the function of DNA, RNA, or protein or by inhibiting cell cycle progression. In some embodiments, the drug may include a topoisomerase inhibitor, and in one embodiment, may include a topoisomerase I inhibitor. In some embodiments, the drug may include exatecan or a derivative thereof. The exatecan is a topoisomerase I inhibitor that stabilizes the cleavage complex formed by topoisomerase I during DNA replication, thereby inducing DNA double-strand breaks and ultimately inducing apoptosis. Exatecan has high cell permeability and may exhibit a bystander effect on adjacent tumor cells after release. The exatecan derivative may include a form in which one or more substitutions or modifications are introduced while maintaining the structure of the reference compound, and may be designed to control the activity, stability, or solubility of the drug. In some embodiments, the exatecan derivative may comprise a structure in which one or more functional groups are substituted, added, or modified while maintaining the basic framework of exatecan.
[0233] In some embodiments, the drug may be selected from the group consisting of amanitin, duocamycin, oristatin, oristatin F (AF), monomethyl oristatin F (MMAF), metansine, metansine (DM1), ravtansine (DM4), tubulaisine, calikiamycin, camptothecin, SN-38, exatecan, Maaa-1181a, taxol, daunomycin, vinblastine, doxorubicin, methotrexate, pyrrolobenzodiazepine (PBD) and its dimers, indylinobenzodiazepine (IBD) and its dimers, or their radioisotopes and / or pharmaceutically acceptable salts.
[0234] In other embodiments, the drug may be an immunomodulatory compound that modulates an immune response. In some embodiments, the immunomodulatory compound may include cytokines such as interleukin (IL-2, IL-12, etc.), interferon, and tumor necrosis factor (TNF), immune checkpoint modulators, or small molecule compounds that modulate the activity or function of immune cells.
[0235] In another embodiment, the drug may be a degradation compound that induces the degradation of a target protein. In some embodiments, the degradation compound may include a dual-functional compound that simultaneously binds to the target protein and a protein mediating the ubiquitin-proteasome pathway, and may include, for example, a PROTAC (proteolysis-targeting chimera) or a compound having a similar mechanism of action.
[0236] In some embodiments, the drug may include a carboxyl-containing drug, a thiol-containing drug, an amino-containing drug, or a hydroxyl-containing drug.
[0237] Depending on the type of functional group of the drug, the method of binding with the self-sacrificial spacer unit (Y) varies. Carboxyl-containing drugs can be linked to the Y residue through ester or amide bonds, thiol-containing drugs through disulfide or thioether bonds, amino-containing drugs through amide or carbamate bonds, and hydroxyl-containing drugs through carbonate, ester, or carbamate bonds.
[0238] An ADC according to the present invention may have a structure in which two or more drugs are bound to a single antibody or antigen-binding fragment. In some embodiments, the two or more drugs may be of the same type or different from each other.
[0239] The release of a drug in an ADC according to the present invention can be controlled by a linker structure. In particular, by a structure comprising a beta-glucuronide linker and a self-sacrificial spacer, the drug can be selectively released into the intracellular or tumor microenvironment.
[0240] The physical properties of ADCs, particularly hydrophobicity, directly affect their blood stability, non-specific binding, pharmacokinetics (PK), and therapeutic efficacy. Excessively hydrophobic ADCs can lead to increased non-specific interactions with serum proteins, accelerated clearance in the body, and potential aggregation. Therefore, maintaining an appropriate hydrophilic-hydrophobic balance is a critical technical challenge in ADC development.
[0241] In the present invention, the beta-D-glucuronide sugar residue structurally contains a carboxylic acid group and a plurality of free hydroxyl groups, and the inventors noted that this structural characteristic can substantially contribute to the physical properties of the ADC. As confirmed in the examples, the ADC containing the beta-glucuronide linker exhibited lower hydrophobicity compared to the ADC having the amino acid linker. In particular, the fact that the ADC without PEG exhibited higher hydrophilicity than the ADC containing PEG (PEG8) is an unexpected result for the inventors, suggesting that the contribution of the sugar residue itself to hydrophilicity in the beta-glucuronide linker structure may be higher than previously expected.
[0242] In addition, in some embodiments, the ADC according to the present invention can exhibit excellent physical properties even though it includes a linker that does not contain PEG. For example, the inventors compared ADCs having different linker structures and confirmed that an ADC containing a specific beta-glucuronide linker can exhibit improved hydrophilicity compared to an ADC with a linker containing PEG. The level of hydrophilicity of the ADC can be evaluated through HIC (hydrophobic interaction chromatography) analysis, and a shorter elution time indicates greater hydrophilicity. In particular, HIC analysis results confirmed that an ADC having a linker structure that does not contain some PEG can exhibit higher hydrophilicity than an ADC containing PEG.
[0243] The drug-antibody ratio (DAR) of an ADC is a parameter that affects the efficacy and toxicity of the ADC. If the DAR is too low, it is difficult to exert sufficient cytotoxic efficacy, while if the DAR is too high, it may lead to increased hydrophobicity, aggregation, reduced stability, and increased non-specific toxicity of the ADC. DAR measurement can be performed using various methods, including liquid chromatography / mass spectrometry (LC / MS), UV-Vis absorbance analysis, HIC, or RP-HPLC. Various DAR values may be targeted depending on the number of antibody conjugation sites, the reactivity of the linker-payload, and the therapeutic purpose.
[0244] An ADC according to the present invention can be prepared by covalently linking a linker-drug conjugate (linker-payload) to an antibody or antigen-binding fragment. Generally, it can be prepared by first synthesizing a linker-payload intermediate and then reacting it with an antibody. Conjugation of the antibody and the linker can be performed using reactive residues of the antibody, for example, by utilizing a Michael addition reaction through the thiol group of a cysteine residue of the antibody or the formation of an amide bond through the amino group of a lysine residue. In one embodiment, the antibody can be prepared by exposing the thiol group of a cysteine residue through a partial reduction treatment and then reacting it with a linker-payload intermediate containing a maleimide group. After the conjugation reaction, the ADC can be purified by methods such as size exclusion chromatography (SEC), hydrophobic interaction chromatography (HIC), or ultrafiltration. The target DAR can be controlled by adjusting the equivalent weight of the linker-payload, reaction conditions, and the number of conjugable sites of the antibody.
[0245] In one embodiment, the ADC according to the present invention may be prepared by maleimide-thiol conjugation. Specifically, the antibody is partially reduced by a reducing agent such as tris(2-carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT) to selectively open the interchain disulfide bond, thereby exposing the free thiol group of the cysteine residue. Subsequently, when a linker-payload intermediate containing a maleimide group is treated with an appropriate equivalent amount, a succinimide thioether bond is formed between the maleimide group and the thiol group by Michael addition. The reaction may be carried out in an aqueous buffer solution (e.g., PBS, borate buffer) at room temperature, and after the reaction is complete, the unreacted linker-payload may be removed by methods such as dialysis, size exclusion chromatography (SEC), or ultrafiltration.
[0246] Furthermore, ADCs containing the above linker structure can maintain excellent cytotoxicity at the cellular level or exhibit enhanced activity. For example, in a comparison between ADCs containing different linkers, it was confirmed that ADCs containing a specific structure can exhibit equivalent or superior cell growth inhibitory effects.
[0247] Furthermore, evaluation results in animal models confirmed that an ADC containing the beta-glucuronide linker can exhibit a significant tumor growth inhibitory effect. In particular, it was confirmed that the efficacy may vary depending on structural differences of the stretcher unit, and that an ADC containing some of the structures can exhibit a superior tumor inhibitory effect compared to an ADC containing other structures.
[0248] Therefore, the ADC according to the present invention can simultaneously achieve excellent hydrophilicity and antitumor effects without including PEG, and can simultaneously improve physical properties and efficacy through the optimization of the linker structure.
[0249] 3. Uses
[0250] The ADC described in the present invention may be useful for the treatment or prevention of cancer.
[0251] In one embodiment, the cancer may include a solid tumor or a blood cancer, and the type of cancer is not limited to a specific tissue, organ, or cell type. Additionally, the medical use according to the present invention may be performed as monotherapy or in combination with other anticancer agents, immunotherapies, radiation therapy, or surgery, and the in vivo stability and functional characteristics of the ADC may be maintained even under such combination therapy.
[0252] One aspect of the present invention provides a pharmaceutical composition for cancer treatment comprising an ADC according to the present invention.
[0253] In one embodiment, the pharmaceutical composition may include a pharmaceutically acceptable carrier, diluent, or excipient, and these components may be selected within a range that does not impair the physical and chemical stability, biological activity, or suitability for administration of the ADC according to the present invention. The pharmaceutically acceptable carrier, diluent, or excipient may be a material commonly used in the art and may be mixed or formulated with the protein according to the present invention.
[0254] The above pharmaceutical composition may be prepared according to conventional formulation methods and may be provided as an injectable, drip, oral, inhalant, topical, or sustained-release formulation depending on the route of administration. In one embodiment, the pharmaceutical composition may be a liquid or solid formulation suitable for intravenous, subcutaneous, intramuscular, intraperitoneal, or topical administration.
[0255] Additionally, the pharmaceutical composition may include a buffer, an isotonic agent, a stabilizer, a preservative, a surfactant, or an antioxidant as needed, and these components may be selected within the range commonly used in the field of protein formulations. The pharmaceutical composition may be provided in a single dose or multiple dose formulation.
[0256] In one embodiment, the pharmaceutical composition of the present invention may contain an ADC as described herein in a therapeutically effective amount.
[0257] Herein, “therapeutically effective content” means an amount sufficient to produce one or more biological effects related to the treatment or prevention of a disease when the ADC according to the present invention is administered to a subject, and includes an amount within a range that does not cause excessive toxicity or undesirable side effects.
[0258] The above therapeutically effective content may vary depending on the subject's condition, the type and severity of the disease, the route of administration, the frequency of administration, the formulation, or whether combination therapy is used, and such differences or variations are understood to be included within the scope of the technical concept of the present invention.
[0259] Regarding the formulation stability of the ADC of the present invention, freeze / thaw cycle tests were performed, and it was confirmed that the quality characteristics of the ADC (monomer purity, DAR, aggregate formation, etc.) remained stable without significant changes even after repeated freeze-thaw treatments. This experimentally supports the fact that the pharmaceutical composition containing the ADC of the present invention can maintain its quality even under standard pharmaceutical storage and distribution conditions.
[0260] The pharmaceutical composition according to the present invention can be easily prepared and practiced by a person skilled in the art without requiring excessive experimentation or creative effort, based on the description provided herein and general skills and knowledge known in the art. Pharmaceutically acceptable carriers, excipients, stabilizers, and delivery systems that may be used in the pharmaceutical composition of the present invention include materials and formulation techniques known in the art, and such differences or variations are understood to be included within the scope of the technical concept of the present invention.
[0261] One aspect of the present invention provides a cancer treatment method comprising administering an ADC according to the present invention to a patient who requires cancer treatment.
[0262] In one embodiment, the medical use includes the treatment or prevention of a disease, and the method may include alleviating symptoms of the disease, inhibiting progression, or reducing the risk of occurrence or recurrence of the disease by administering an ADC to the individual.
[0263] In one embodiment, the medical use is the treatment or prevention of cancer. The cancer may include solid tumors or blood cancers, and the type of cancer is not limited to a specific tissue, organ, or cell type. The treatment method of the present invention may be performed for the purpose of preventing the occurrence of cancer, alleviating symptoms of cancer that has already occurred, inhibiting tumor growth, delaying progression, or preventing recurrence.
[0264] In one embodiment, the individual may be a human and may include a non-human mammal as needed. The treatment method of the present invention may be performed for the purpose of preventing a disease, or for the purpose of alleviating symptoms of a disease that has already occurred, inhibiting progression, or restoring tissue function.
[0265] In one embodiment, the treatment method may include administering the ADC of the present invention in a therapeutically effective amount.
[0266] Herein, “therapeutically effective amount” means an amount sufficient to induce one or more biological effects related to the treatment or prevention of a disease when the ADC according to the present invention is administered to an individual, and includes an amount within a range that does not cause excessive toxicity or clinically undesirable side effects.
[0267] The above therapeutically effective amount may vary depending on the type and severity of the disease, the purpose of treatment (treatment or prevention), the individual's condition, the route of administration, the frequency of administration, the form of the protein used (ADC), and whether concomitant treatment is used.
[0268] The above ADC may be administered alone or may be administered in combination with other therapeutic agents, such as anticancer agents, immunotherapies, immunomodulators, antibody therapies, cell therapies, or radiation therapy. Combination administration may be performed with the same or different formulations, and may be carried out simultaneously, sequentially, or at regular intervals.
[0269] The present invention will be explained in detail below by the following examples. However, the following examples are merely illustrative of the present invention, and the present invention is not limited thereto.
[0270]
[0271] Examples
[0272] Example 1: Linker-Payload (LP) Synthesis
[0273] In this embodiment, a method for synthesizing linker-payload (LP) compounds LP1 to LP7 used in the manufacture of antibody-drug conjugates (ADCs) is described. Each LP was prepared as follows.
[0274] LP1: PEG8-VA-Exa
[0275]
[0276] HOBt (562 mg, 4.16 mmol, 1.2 equivalents) and DIC (2.63 g, 20.81 mmol, 3.22 mL, 6.0 equivalents) were added to a solution of Compound 1 (1 g, 3.47 mmol, 1.0 equivalent) and Compound 1-1 (553 mg, 1.04 mmol, 0.3 equivalent) dissolved in DMF (10 mL). The reaction mixture was stirred at 25°C for 1 hour. LC-MS analysis revealed that Compound 1 was completely consumed and a single major peak corresponding to the target product was identified. The crude reaction mixture was purified using preparative high-performance liquid chromatography (TFA conditions), resulting in Compound 2 (1.49 g, 2.11 mmol) as a yellow solid (yield 12.1%).
[0277] LCMS: Calculated mass value is 705.3, observed mass value is [M+H] + =706.4.
[0278] TFA (6.14 g, 53.8 mmol, 4 mL, 25.5 equivalents) was added to a solution of Compound 2 (1.49 g, 2.11 mmol, 1.0 equivalent) dissolved in DCM (16 mL). The reaction mixture was stirred at 25°C for 1 hour. LC-MS analysis revealed that Compound 2 was completely consumed and a single major peak corresponding to the target product was identified. The reaction mixture was concentrated under reduced pressure to remove the solvent. The resulting crude residue was purified using preparative high-performance liquid chromatography (TFA conditions), yielding Compound 3 (667 mg, 1.10 mmol, 52.2% yield) as a yellow solid.
[0279] LCMS: Calculated mass value is 605.3, observed mass value is [M+H] + =606.3.
[0280] DIEA (4.48 mg, 34.68 μmol, 6.05 μL, 2.0 equivalents) was added to a solution of Compound 3 (10.5 mg, 17.32 μmol, 1.0 equivalent) and Compound 4 (14.35 mg, 20.79 μmol, 1.2 equivalents) dissolved in DMF (0.4 mL). The reaction mixture was stirred at 25°C for 0.5 hours. LC-MS analysis revealed that Compound 3 was completely consumed and a single major peak corresponding to the target product was identified. The reaction mixture was purified using preparative high-performance chromatography (FA conditions), resulting in LP1 (9.3 mg, 7.87 μmol, 45.7% yield) as a white solid.
[0281] LCMS: Calculated mass value is 1179.5, observed mass value is [M+H] + =1180.6.
[0282] LP2: PEG8-VCit-Exa
[0283]
[0284] HOBt (86.6 mg, 641 μmol, 1.2 equivalents) and DIC (496 μL, 3.20 mmol, 6.0 equivalents) were added to a solution of Compound 1 (200 mg, 534 μmol, 1.0 equivalent) and Compound Exatecan (85.2 mg, 160 μmol, 0.3 equivalents) dissolved in DMF (2 mL). The reaction mixture was stirred at 25°C for 3 hours. The reaction progress was monitored using liquid chromatography-mass spectrometry (LCMS). The crude reaction mixture was purified using preparative high-performance chromatography (TFA conditions) and performed for 10 minutes under a 32-62% B gradient using a Welch Xtimate C18 column (150 x 25 mm, 5 μm) with water and ACN as the mobile phase. As a result, compound 2 (101 mg, 128 μmol, 23.9% yield) was obtained as a yellow solid.
[0285] LCMS: Calculated mass value is 791.8, observed mass value is [M+H] + =792.3.
[0286] 20% TFA was added to a solution of Compound 2 (101 mg, 128 μmol, 1.0 equivalent) dissolved in DCM (1 mL). The reaction mixture was stirred at 25°C for 1 hour. Liquid chromatography-mass spectrometry (EC13682-66-P2A; product Rt = 0.32 min) analysis confirmed that the starting material was completely consumed. Subsequently, the reaction mixture was poured into cold isopropyl ether (50 mL) and stirred for 30 minutes. The resulting precipitate was collected by filtration and concentrated to obtain the residue. The solid was dissolved in DMF and purified using preparative high-performance chromatography (TFA conditions). As a result, Compound 3 (61.6 mg, 89.1 μmol, 69.8% yield) was obtained as a yellow solid.
[0287] LCMS: Calculated mass value is 691.8, observed mass value is [M+H] + =692.4.
[0288] DIEA (12.9 μL, 74.0 μmol, 2.0 equivalents) was added to a solution of compounds 2-3 (25.6 mg, 37.0 μmol, 1.0 equivalent) and compounds 4 (128 mg, 185 μmol, 5.0 equivalents) dissolved in DMF (1 mL). The reaction mixture was stirred at 0°C for 1 hour, and the reaction progress was monitored by liquid chromatography-mass spectrometry. The crude residue was purified using preparative high-performance chromatography (TFA conditions), and as a result, LP2 (5.3 mg, 3.84 μmol, 10.4% yield, >99.9% purity, TFA) was obtained as a yellow solid.
[0289] LCMS: Calculated mass value is 1266.3, observed mass value is [M+H] + =1266.8.
[0290] LP3: PEG8-BG-Exa
[0291]
[0292] Pd / C (10%, 3.4 g) was added under a nitrogen (N2) atmosphere to a solution in which methyl (2S,3S,4S,5R,6S)-3,4,5-triacetoxy-6-[4-(hydroxymethyl)-2-nitrophenoxy]tetrahydropyran-2-carboxylate (10.0 g, 20.6 mmol) was dissolved in THF (100 mL) and EtOAc (100 mL). The suspension was degassed and then purged with hydrogen (H2) three times. The reaction mixture was stirred at 25°C for 16 hours under a hydrogen (15 psi) atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to obtain the target compound, methyl (2S,3S,4S,5R,6S)-3,4,5-triacetoxy-6-[2-amino-5-(hydroxymethyl)phenoxy]tetrahydropyran-2-carboxylate, as a white solid (9.19 g, yield 84.6%).
[0293] LCMS: m / z = 456.1 (M+H)+
[0294] EEDQ (706 mg, 0.85 mmol) and 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonoxa-4-azahentriacontan-31-oxan (1.04 g, 1.57 mmol) were added to a solution of methyl (2S,3S,4S,5R,6S)-3,4,5-triacetoxy-6-[2-amino-5-(hydroxymethyl)phenoxy]tetrahydropyran-2-carboxylate (650 mg, 1.43 mmol) dissolved in THF (7 mL). The reaction mixture was stirred at 25°C for 16 hours. The reaction mixture was diluted with water (10 mL) and extracted with CH2Cl₂ (10 mL x 3). The organic layers were combined, dried with Na2SO₄, and concentrated under reduced pressure to obtain a residue. The obtained residue was purified using column chromatography (SiO₂, CH₂Cl₂ / MeOH = 1 / 0 → 15 / 1) to obtain the target compound, (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonaoxa-4-azahentriacontan-31-amido)-5-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate, as a yellow solid (1.33 g, yield 72.8%).
[0295] LCMS: m / z = 1101.6 (M+H)+
[0296] (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonaoxa-4-azahentriacontan-31-amido)-5-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (1.00 g, 908 μmol) was dissolved in CH2Cl2 (10 mL), to which pyridine (Py, 359 mg, 4.54 mmol, 366 μL) and (4-nitrophenyl)carbonochloridate (275 mg, 1.36 mmol) were added. The reaction mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated until dry to obtain a residue. The obtained residue was purified using column chromatography (SiO2, CH₂Cl₂ / MeOH = 1 / 0 → 20 / 1) to obtain the target compound, (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonaoxa-4-azahentriacontan-31-amido)-5-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate, as a colorless oil (791 mg, yield 64.0%).
[0297] LCMS: m / z = 1266.1 (M+H)+
[0298] 1H NMR: (400 MHz, DMSO-d6):
[0299] δ 8.78 (s, 1H), 8.26-8.34 (m, 2H), 8.06 (s, 1H), 7.88 (d, J = 7.6 Hz, 2H), 7.68 (d, J = 7.6 Hz, 2H), 7.53-7.60 (m, 2H), 7.41 (t, J = 7.6 Hz,, 2H), 7.32 (t, J = 7.6 Hz, 3H), 7.22 (dd, J = 8.4, 2.0 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 5.65 (d, J = 8.0 Hz, 1H), 5.46-5.54 (m, 1H), 5.17-5.26 (m, 3H), 5.07 (t, J = 10.0 Hz, 1H), 4.73 (d, J = 10.0 Hz, 1H), 4.28 (d, J = 6.8 Hz, 2H), 4.16-4.23 (m, 1H), 3.70 (t, J = 6.4 Hz, 2H), 3.63 (s, 3H), 3.51-3.54 (m, 4H), 3.46-3.50 (m, 26H), 3.10-3.15 (m, 2H), 2.56-2.62 (m, 2H), 1.99-2.04 (m, 9H)
[0300] (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonaoxa-4-azahentriacontan-31-amido)-5-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (791 mg, 625 μmol)) was dissolved in pyridine (8 mL) in a solution of HOBt (169 mg, 1.25 mmol), (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-5,9-dione (272 mg, 625 μmol) and DIEA (161 mg, 1.25 mmol, 218 μL) were added. The reaction mixture was stirred at 25°C for 2 hours. Subsequently, the reaction mixture was diluted with water (10 mL) and extracted with CH2Cl₂ (10 mL x 3). The organic layers were combined, dried with Na2SO₄, and concentrated under reduced pressure to obtain the residue. The obtained residue is purified using column chromatography (SiO2, CH₂Cl₂ / MeOH = 1 / 0 → 15 / 1), thereby the target compound is (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonaoxa-4-azahentriacontan-31-amido)-5-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate yellow It was obtained as a solid (471 mg, yield 46.4%).
[0301] LCMS: m / z = 1563.5 (M+H)+
[0302] (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonaoxa-4-azahentriacontan-31-amido)-5-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl LiOH·H2O (32.2 mg, 768 μmol) and H2O (1 mL) were added to a solution of triacetate (200 mg, 128 μmol) dissolved in THF (1 mL). The reaction mixture was stirred at 25°C for 4 hours. Subsequently, the pH of the reaction mixture was adjusted to 2 using a 1 N HCl solution. Afterward, the reaction mixture was purified using prep-HPLC (Column: Welch Xtimate C18, 40 x 200 mm, 7 μm; Mobile phase: [water(TFA)-ACN]; Gradient: 8%→48% B for 20 minutes), (2S,3S,4S,5R,6S)-6-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-5-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-diox So-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxymethyl]phenoxy]-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid was obtained as a yellow solid (87.1 mg, yield 51.9%).
[0303] LCMS: m / z = 1200.4 (M+H)+
[0304] (2S,3S,4S,5R,6S)-6-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-5-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo- DIEA (6.86 mg, 53.1 μmol, 9.25 μL) and (2,5-dioxopyrrolidine-1-yl)6-(2,5-dioxopyrrol-1-yl)hexanoate (9.82 mg, 31.9 μmol) were added to a solution in which 8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxymethyl]phenoxy]-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (31.9 mg, 26.5 μmol) was dissolved in DMF (0.5 mL). The reaction mixture was stirred at 25°C for 2 hours. The resulting residue was subsequently purified using prep-HPLC (Column: F-Prepulite XP tC18, 40 χ 200 mm, 7 μm; Mobile phase: [water(TFA)-ACN]; Gradient: 16%→56% for 20 min). As a result, (2S,3S,4S,5R,6S)-6-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[6-(2,5-dioxopyrrolidine-1-yl)hexanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-5-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy- 19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxymethyl]phenoxy]-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid was obtained as a yellow solid (13.02 mg, yield 35.2%, purity 100%).
[0305] LCMS: m / z = 1394.5 (1 / 2M+H)+
[0306] 1H NMR: (400 MHz, DMSO-d6):
[0307] δ 9.09 (s, 1H), 8.20 (s, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.74-7.83 (m, 2H), 7.31 (s, 1H), 7.07-7.12 (m, 2H), 6.99 (s, 2H), 5.44 (s, 2H), 5.24-5.31 (m, 3H), 5.06 (br s, 2H), 4.84 (d, J = 7.2 Hz, 1H), 3.87 (d, J = 9.6 Hz, 1H), 3.63 (t, J = 6.4 Hz, 2H), 3.45-3.51 (m, 36H), 3.13-3.18 (m, 4H), 3.07-3.11 (m, 1H), 2.55-2.65 (m, 2H), 2.52-2.55 (m, 2H), 2.38 (s, 3H), 2.15-2.21 (m, 2H), 2.02 (t, J = 7.2 Hz, 2H), 1.83-1.91 (m, 2H), 1.42-1.49 (m, 4H), 1.13-1.20 (m, 2H), 0.88 (t, J = 7.2 Hz, 3H)
[0308] LP4: PSAR10-BG-Exa
[0309]
[0310] Aluminum powder (28.2 g, 1.05 mol) was placed in THF (120 mL) and loaded into a three-necked flask equipped with a condenser and a dropping funnel. After adding a catalytic amount of HgCl₂ (4.74 g, 17.4 mmol, 872 μL), the mixture was stirred for 0.5 hours at 25°C under a nitrogen (N₂) atmosphere. Subsequently, a solution of 1 / 10 of 3-bromoprop-1-phosphorus (155 g, 1.05 mol, 112 mL) dissolved in THF (320 mL) was added to initiate the formation of the aluminum compound (formation of a dark solution accompanied by THF reflux, under an N₂ atmosphere). Subsequently, a solution of the remaining 9 / 10 of 3-bromoprop-1-phosphorus (155 g, 1.05 mol, 112 mL) dissolved in THF (320 mL) was added dropwise at 25°C under a nitrogen atmosphere. The reaction mixture was stirred at 25°C for 2 hours, followed by 30 minutes at 65°C. After cooling the reaction mixture to 25°C, a solution of 4-hydroxy-3-nitrobenzaldehyde (29.2 g, 174 mmol) dissolved in anhydrous THF (400 mL) was added dropwise, and the mixture was stirred at 25°C for 12 hours under a nitrogen atmosphere. TLC (petroleum ether:ethyl acetate = 3:1, Rf = 0.4) analysis confirmed that the starting material was completely consumed and a new product spot was formed. After cooling the reaction mixture to 0°C, it was added to ice (300 mL) and a 1 N HCl solution (200 mL) and stirred for 0.5 hours. Subsequently, the reaction mixture was extracted with ethyl acetate (EtOAc, 100 mL × 3). The organic layers were combined, dried with anhydrous Na₂SO₄, and filtered; the filtrate was then concentrated to obtain the residue. The obtained residue was purified using flash silica gel chromatography (ISCO®; 120 g SepaFlash® silica column, elution conditions: ethyl acetate / petroleum ether 0–15% gradient, flow rate 100 mL / min) to obtain the target compound, 4-(1-hydroxybut-3-inyl)-2-nitrophenol, in the form of a black oil (19 g, yield 50).1%, purity 95%).
[0311] LCMS: m / z =206.1 (MH)+
[0312] N'-[2-[2-(dimethylamino)ethyl-methylamino]ethyl]-N,N,N'-trimethyl-ethane-1,2-diamine (3.89 g, 16.9 mmol, 0.7 equivalents) was added to a solution of Ag₂CO₃ (24.6 g, 89.3 mmol, 3.7 equivalents) dissolved in MeCN (50 mL) under a nitrogen (N₂) atmosphere. After stirring the reaction mixture at 25°C for 2 hours, a solution of 4-(1-hydroxybut-3-inyl)-2-nitrophenol (5 g, 24.13 mmol, 1 equivalent) and methyl (3S,4S,6S)-3,4,5-triacetoxy-6-bromo-tetrahydropyran-2-carboxylate (10.5 g, 26.6 mmol, 1.1 equivalent) dissolved in MeCN (50 mL) was added dropwise at 0°C. The reaction mixture was then stirred at 25°C for 5 hours. The reaction was terminated with water (100 mL) and extracted with ethyl acetate (50 mL × 3). The organic layers were combined, washed with 1 M HCl, dried with MgSO₄, filtered, and concentrated under reduced pressure. The obtained residue was purified using flash silica gel chromatography (ISCO®; 80 g SepaFlash® silica column, elution conditions: ethyl acetate / petroleum ether 0–50% gradient, flow rate 100 mL / min) to obtain the target compound, methyl (3S,4S,6S)-3,4,5-triacetoxy-6-[4-(1-hydroxybut-3-inyl)-2-nitrophenoxy]tetrahydropyran-2-carboxylate, as a pale yellow solid (7 g, yield 51.5%, purity 93.4%).
[0313] LCMS: m / z = 522.1 (MH)+
[0314] Pyridine (2.61 g, 32.9 mmol, 2.66 mL, 2.5 equivalents) was added at 0°C to a solution in which methyl (3S,4S,6S)-3,4,5-triacetoxy-6-[4-(1-hydroxybut-3-inyl)-2-nitrophenoxy]tetrahydropyran-2-carboxylate (6.9 g, 13.18 mmol, 1 equivalent) and (4-nitrophenyl) carbonochloridate (5.31 g, 26.36 mmol, 2 equivalents) were dissolved in DCM (100 mL). The reaction mixture was stirred at 25°C for 1 hour. After the reaction was complete, a saturated aqueous NaHCO₃ solution (100 mL) was added to terminate the reaction, and the mixture was extracted with DCM (100 mL × 3). The organic layer was combined and washed with saturated saline (100 mL), dried with MgSO₄, filtered, and then concentrated under reduced pressure. The resulting residue was purified using flash silica gel chromatography (ISCO®; 80 g SepaFlash® silica column, elution conditions: ethyl acetate / petroleum ether 0–45% gradient, flow rate 80 mL / min) to obtain the target compound, methyl (3S,4S,6S)-3,4,5-triacetoxy-6-[2-nitro-4-[1-(4-nitrophenoxy)carbonyloxybut-3-inyl]phenoxy]tetrahydropyran-2-carboxylate, as a pale yellow solid (8.5 g, yield 88.9%, purity 95%).
[0315] LCMS: m / z =711.1 (M+Na)+
[0316] Methyl (3S,4S,6S)-3,4,5-triacetoxy-6-[2-nitro-4-[1-(4-nitrophenoxy)carbonyloxybut-3-inyl]phenoxy]tetrahydropyran-2-carboxylate (8.5 g, 12.3 mmol, 1 equivalent), (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione methanesulfonate (6.56 g, 12.3 mmol, 1 equivalent) and HOBt (1.67 g, 12.3 mmol, 1 equivalent) were mixed with DMF (56 Pyridine (14 mL) was added at 0°C to a solution dissolved in mL). The reaction mixture was stirred at 25°C for 2 hours. After the reaction was complete, the reaction mixture was concentrated to obtain a residue. The obtained residue was purified using flash silica gel chromatography (ISCO®; 120 g SepaFlash® silica column, elution conditions: ethyl acetate / petroleum ether 0–80% gradient, flow rate 100 mL / min) to obtain the target compound, methyl (3S,4S,6S)-3,4,5-triacetoxy-6-[4-[1-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxy]but-3-inyl]-2-nitrophenoxy]tetrahydropyran-2-carboxylate was obtained as a white solid (12.0 g, preparation).
[0317] LCMS: m / z =985.1(M+H)+
[0318] Methyl (3S,4S,6S)-3,4,5-triacetoxy-6-[4-[1-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxy]but-3-inyl]-2-nitrophenoxy]tetrahydropyran-2-carboxylate (6.00 g, 6.09 mmol, 1 equivalent) was dissolved in methanol (MeOH, 80 mL) and THF (80 mL). The reaction mixture was neutralized with acetic acid to adjust the pH to 7, and then concentrated under reduced pressure. The obtained residue was purified using PREP-HPLC (Column: Phenomenex Luna C18, 250 × 70 mm, 10 μm; Mobile phase: [Water (TFA)-ACN]; Gradient: 15% → 45% B, 38 min) to obtain the target compound. (3S,4S,6S)-6-[4-[1-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxy]but-3-inyl]-2-nitrophenoxy]-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid was obtained as a pale yellow solid (10.0 g, preparation).
[0319] LCMS: m / z =845.2 (M+H)+
[0320] (3S,4S,6S)-6-[4-[1-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.0²,14.0⁴,13.0 6 ,11.0 20,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxy]but-3-inyl]-2-nitrophenoxy]-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid (340 mg, 402 μmol, 1.00 equivalents) and 2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-(2-azidoethylamino)acetyl]-methylamino] Copper sulfate pentahydrate (20.1 mg, 80.5 μmol, 0.200 equivalents) and buffer solution (3.00 mL) were added to a solution prepared by dissolving 402 μmol, 1.00 equivalents) in DMSO (3.00 mL). The reaction mixture was stirred at 40°C for 2 hours. After obtaining the residue by concentrating the reaction mixture under reduced pressure, the residue was purified using PREP-HPLC (Column: CD05-Phenomenex Luna C18, 150 × 40 × 10 μm; Mobile phase: [Water (TFA)-ACN]; Gradient: 8% → 38% B, 10 min) to obtain the target compound
[0321] (3S,4S,6S)-6-[4-[2-[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[Carboxymethyl(methyl)amino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]amino ]ethyl]triazole-4-yl]-1-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxy]ethyl]-2-nitrophenoxy]-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid was obtained as a yellow solid (440 mg, yield 85.4%, purity 98.3%).
[0322] 1H NMR: (400 MHz, CD3OD).
[0323] δ (ppm) 7.22-8.22 (m, 7H), 5.89-6.21 (m, 1H), 5.47-5.62 (m, 1H), 5.32-5.42 (m, 1H), 5.18-5.29 (m, 2H), 4.89 (s, 22H), 4.30-4.44 (m, 8H), 4.04-4.22 (m, 10H), 3.48-3.69 (m, 5H), 2.84-3.10 (m, 29H), 2.25-2.42 (m, 4H), 1.95 (br d, J = 6.3 Hz, 2H), 0.99 (d, J = 5.0 Hz, 3H).
[0324] LCMS: m / z =1699.6(M+H)+
[0325] TEA (57.1 mg, 564 μmol, 78.6 μL, 3.00 equivalents) and COMU (96.7 mg, 225 μmol, 1.20 equivalents) were added to a solution of 2-[4-(2,5-dioxopyrole-1-yl)phenyl]acetic acid (65.3 mg, 282 μmol, 1.5 equivalents) dissolved in DMF (6.00 mL), and the mixture was stirred at 25°C for 5 minutes. Subsequently, to the above mixture (3S,4S,6S)-6-[4-[2-[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[Carboxymethyl(methyl)amino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-2-oxo ethyl]amino]ethyl]triazole-4-yl]-1-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxy]ethyl]-2-nitrophenoxy]-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid (320 mg, 188 μmol, 1.00 equivalents) was added and stirred at 25°C for 1 hour. After obtaining the residue by concentrating the reaction mixture under reduced pressure, the residue was purified using prep-HPLC (column: CD05-Phenomenex Luna C18, 150 × 40 × 10 μm; mobile phase: [water(TFA)-ACN]; gradient: 13% → 43% B, 15 min).As a result, the target compound (3S,4S,6S)-6-[4-[2-[1-[2-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[carboxymethyl(methyl)amino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-methylamino]-2-oxoethyl]-[2-[4-(2, 5-dioxopyrrol-1-yl)phenyl]acetyl]amino]ethyl]triazole-4-yl]-1-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptane-23-yl]carbamoyloxy]ethyl]-2-nitrophenoxy]-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid was obtained as a yellow solid (35.3 mg, purity 95.4%).
[0326] 1H NMR: (400 MHz, DMSO-d6)
[0327] δ (ppm) 12.8 (br s, 1H), 8.03-8.18 (m, 1H), 7.73-7.97 (m, 3H), 7.56-7.72 (m, 1H), 7.38-7.49 (m, 1H), 7.28-7.34 (m, 1H), 7.11-7.23 (m, 5H), 6.33-6.70 (m, 1H), 5.90-6.04 (m, 1H), 5.07-5.47 (m, 7H), 3.91-4.41 (m, 29H), 3.21-3.43 (m, 7H), 2.63-3.08 (m, 34H), 2.36 (br s, 3H), 2.00-2.20 (m, 2H), 1.78-1.95 (m, 2H), 0.88 (br t, J = 7.3 Hz, 3H)..
[0328] LCMS: m / z =1912.4(M+H)+
[0329] LP5: BG-Exa
[0330]
[0331] After adding pyridine (7.40 g, 93.5 mmol, 7.55 mL) to a solution in which methyl (2S,3S,4S,5R,6S)-3,4,5-triacetoxy-6-[2-[3-(9H-fluorene-9-ylmethoxycarbonylamino)propanoylamino]-4-(hydroxymethyl)phenoxy]tetrahydropyran-2-carboxylate (14.0 g, 18.7 mmol) was dissolved in CH₂Cl₂ (200 mL), (4-nitrophenyl)carbonochloridate (5.65 g, 28.0 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours. After the reaction was complete, the reaction mixture was distributed between CH₂Cl₂ (300 mL) and water (200 mL). After washing the organic layer with water (200 mL × 3), it was dried with anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain a residue. The obtained residue was purified using column chromatography (SiO₂, petroleum ether / ethyl acetate = 100:1 → 1:1) to obtain the target compound, (2S,3R,4S,5S,6S)-2-(2-(3-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)propaneamido)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate, as a white solid (15.1 g, yield 85.2%).
[0332] LCMS: m / z = 914.3 (M+H)+
[0333] (2S,3R,4S,5S,6S)-2-(2-(3-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)propaneamido)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (400 mg, 438 μmol) and HOBt (118 mg, 875 μmol) and DIEA (113 mg, 875 μmol, 152 μL) were added to a solution in which (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16(24),17,19-heptane-5,9-dione (191 mg, 438 μmol) was dissolved in pyridine (6 mL). The reaction mixture was stirred at 30 °C for 1 hour. After the reaction was complete, the reaction mixture was filtered and concentrated under reduced pressure to obtain the residue. The obtained residue was purified using column chromatography (SiO₂, DCM / MeOH = 10:1) to obtain the target compound, (2S,3R,4S,5S,6S)-2-(2-(3-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)propaneamido)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate, as a yellow It was obtained as a solid (320 mg, yield 60.4%).
[0334] LCMS: m / z = 1210.8 (M+H)+
[0335] In a solution prepared by dissolving (2S,3R,4S,5S,6S)-2-(2-(3-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)propaneamido)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (240 mg, 198 μmol) in THF (0.8 mL) LiOH·H₂O (49.9 mg, 1.19 mmol) and water (0.2 mL) were added. The reaction mixture was stirred at 0 °C for 7 hours. After the reaction was complete, the pH of the reaction mixture was adjusted to 4 using acetic acid (AcOH) and then concentrated under reduced pressure. Subsequently, the mixture was purified using PREP-HPLC (TFA conditions; column: F-Prepulite XP tC18, 40 × 200 mm, 7 μm; mobile phase: [water (TFA)-ACN]; gradient: 4% → 44% B, 20 min), thereby obtaining the target compound (2S,3S,4S,5R,6S)-6-(2-(3-aminopropaneamido)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid was obtained as a yellow solid (60.1 mg, yield 35.7%).
[0336] LCMS: m / z = 848.3 (M+H)+
[0337] (2S,3S,4S,5R,6S)-6-(2-(3-aminopropaneamido)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (50 mg, 59.0 μmol) was dissolved in DMF (1 mL) in a solution containing DIEA (22.9 mg, 177 μmol, 30.8 μL) and (2,5-dioxopyrrolidine-1-yl)6-(2,5-dioxopyrrol-1-yl)hexanoate (25.4 mg, 82.6 μmol) was added. The reaction mixture was stirred at 20 °C for 1 hour. After the reaction was complete, the reaction mixture was filtered and concentrated under reduced pressure to obtain the residue. The obtained residue was purified using PREP-HPLC (TFA conditions; column: F-Prepulite XP tC18, 40 × 200 mm, 7 μm; mobile phase: [water (TFA)-ACN]; gradient: 12% → 52% B, 20 min) to obtain the target compound (2S,3S,4S,5R,6S)-6-(2-(3-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)hexanamido)propaneamido)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid was obtained as a yellow solid (24.9 mg, yield 40.2%, purity 98.9%).
[0338] 1H NMR: (400 MHz, CD3OD)
[0339] δ 8.21 (s, 1H), 7.62 (d, J = 12.8 Hz, 2H), 7.20 (d, J = 8.4 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.74 (s, 2H), 5.55-5.62 (m, 1H), 5.41 (d, J = 16.4 Hz, 1H), 5.30-5.36 (m, 1H), 5.16-5.29 (m, 3H), 5.08-5.16 (m, 1H), 3.96 (d, J = 9.6 Hz, 1H), 3.37-3.62 (m, 8H), 3.12-3.22 (m, 2H), 2.52-2.63 (m, 2H), 2.42 (s, 3H), 2.25-2.35 (m, 2H), 2.15 (t, J = 7.2 Hz, 2H), 1.97 (q, J = 7.2 Hz, 2H), 1.53-1.61 (m, 2H), 1.45-1.53 (m, 2H), 1.20-1.28 (m, 2H), 1.02 (t, J = 7.2 Hz, 3H)
[0340] LCMS: m / z = 1041.4 (M+H)+
[0341] LP6: mBG-Exa
[0342]
[0343] HATU (11.7 g, 30.9 mmol) and DIEA (8.00 g, 61.9 mmol, 10.7 mL) were added to a solution in which 5-(hydroxymethyl)-2-(((2S,3R,4S,5S,6S)-3,4,5-triacetoxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)oxy)benzoic acid (10 g, 20.6 mmol) and (9H-fluorene-9-yl)methyl (2-aminoethyl)carbamate (5.83 g, 20.6 mmol) were dissolved in CH₂Cl₂ (100 mL). The reaction mixture was stirred at 25 °C for 1 hour. After the reaction was complete, the reaction mixture was diluted with water (200 mL) and extracted with CH₂Cl₂ (200 mL × 2). The organic layers were combined, dried with anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain a residue. The obtained residue was purified using column chromatography (SiO₂, hexane:ethyl acetate = 100:0 → 0:1) to obtain the target compound, (2S,3R,4S,5S,6S)-2-(2-((2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)ethyl)carbamoyl)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate, as a white solid (15.0 g, yield 79.4%).
[0344] LCMS: m / z = 749.3 (M+H)+
[0345] DIEA (3.88 g, 30.0 mmol, 5.23 mL) was added to a solution in which (2S,3R,4S,5S,6S)-2-(2-((2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)ethyl)carbamoyl)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (15.0 g, 20.0 mmol) and bis(4-nitrophenyl) carbonate (12.1 g, 40.0 mmol) were dissolved in CH₂Cl₂ (200 mL). The reaction mixture was stirred at 25 °C for 3 hours. After the reaction was complete, the reaction mixture was diluted with water (200 mL) and extracted with CH₂Cl₂ (200 mL × 2). The organic layers were combined, dried with anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain a residue. The obtained residue was purified using column chromatography (SiO₂, hexane:ethyl acetate = 100:1 → 1:2) to obtain the target compound, (2S,3R,4S,5S,6S)-2-(2-((2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)ethyl)carbamoyl)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate, as a yellow solid (14.2 g, yield 57.84%).
[0346] LCMS: m / z = 914.2 (M+H)+
[0347] (2S,3R,4S,5S,6S)-2-(2-((2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)ethyl)carbamoyl)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (7.0 g, 7.66 mmol)) dissolved in DMF (70 mL) in a solution of DIEA (1.98 g, 15.3 mmol, 2.67 mL) and (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione (3.34 g, 7.66 mmol) was added. The reaction mixture was stirred at 25 °C for 3 hours. After the reaction was complete, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (EtOAc, 200 mL × 2). The organic layers were combined, washed with saturated saline (brine, 200 mL × 2), dried with anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain the residue. The obtained residue is purified using column chromatography (SiO₂, MeOH:CH₂Cl₂ = 1:100 → 4:96), thereby the target compound is (2S,3R,4S,5S,6S)-2-(2-((2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)ethyl)carbamoyl)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate was obtained as a yellow solid (7.12 g, yield 74.7%).
[0348] LCMS: m / z = 1210.5 (M+H)+
[0349] (2S,3R,4S,5S,6S)-2-(2-((2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)ethyl)carbamoyl)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.00 g, 3.31 mmol) dissolved in THF (50 mL) / H₂O (50 mL) LiOH·H₂O (832 mg, 19.8 mmol) and piperidine (1.69 g, 19.8 mmol, 1.96 mL) were added to the solution. The reaction mixture was stirred at 0 °C for 4 hours. After the reaction was complete, the pH of the reaction mixture was adjusted to 2 using 2 M HCl and then concentrated under reduced pressure. Subsequently, the target compound was purified by PREP-HPLC (Column: F-Welch Xtimate C18, 40 × 200 mm, 7 μm; Mobile phase: [H₂O(0.1% TFA)-ACN]; Gradient: 2% → 42% B, 19.0 min). (2S,3S,4S,5R,6S)-6-(2-((2-aminoethyl)carbamoyl)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid was obtained as a yellow solid (1.70 g, yield 53.39%).
[0350] LCMS: m / z = 848.3 (M+H)+
[0351] (2S,3S,4S,5R,6S)-6-(2-((2-aminoethyl)carbamoyl)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (1.10 g, 1.30 mmol) and 2,5-dioxopyrrolidine-1-yl DIEA (335 mg, 2.59 mmol, 451 μL) was added to a solution of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)hexanoate (400 mg, 1.30 mmol) dissolved in DMF (10 mL). The reaction mixture was stirred at 25 °C for 2 hours. After the reaction was complete, the reaction mixture was concentrated under reduced pressure to obtain the residue. The obtained residue was purified using PREP-HPLC (Column: F-Welch Xtimate C18, 40 × 200 mm, 7 μm; Mobile phase: [H₂O(0.1% TFA)-ACN]; Gradient: 18% → 58% B, 19.0 min) to obtain the target compound (2S,3S,4S,5R,6S)-6-(2-((2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)hexanamido)ethyl)carbamoyl)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid as a yellow solid (625 mg, yield 46.24%, purity 99.83%) I got it.
[0352] 1H NMR: (400 MHz, DMSO-d6)
[0353] δ 8.27 (t, J = 5.2 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.77-7.85 (m, 3H), 7.55 (d, J = 8.4 Hz, 1H), 7.31 (s, 1H), 7.27 (d, J = 8.4 Hz, 1H), 6.99 (s, 2H), 5.44 (s, 2H), 5.28 (br s, 3H), 5.07-5.16 (m, 4H), 3.98 (d, J = 9.2 Hz, 1H), 3.01-3.48 (m, 15H), 2.38 (s, 3H), 2.15-2.21 (m, 2H), 2.04 (t, J = 7.2 Hz, 2H), 1.84-1.91 (m, 2H), 1.43-1.49 (m, 4H), 1.13-1.19 (m, 2H), 0.88 (t, J = 7.2 Hz, 3H)
[0354] LCMS: m / z = 1041.4 (M+H)+
[0355] LP7: PEG8-mBG-Exa
[0356]
[0357] BnBr (4.633 g, 27.087 mmol, 3.222 mL, 1 equivalent) and DIEA (3.501 g, 27.087 mmol, 4.718 mL, 1 equivalent) were added to a THF (40 mL) solution of Compound 1 (4.5 g, 27.087 mmol, 1 equivalent) at room temperature. The reaction mixture was stirred at 25 °C for 16 hours. After the reaction was complete, the crude product was purified by reverse-phase liquid chromatography (40 g C18 column, 60%-80% MeCN elution conditions in water (0.1% FA), 20 min) to obtain Compound 2 (2.5 g, 9.756 mmol, yield 36.017%) in the form of a yellow solid.
[0358] LCMS: m / z = 257.1 (M+H)+
[0359] Ag2O (1.808 g, 7.804 mmol, 253.286 μL, 2 equivalents) and Compound 3 (1.705 g, 4.292 mmol, 1.1 equivalents) were added to a 20 mL ACN solution of Compound 2 (1 g, 3.902 mmol, 1 equivalent) at 0 °C. The reaction mixture was stirred at 25 °C for 16 hours. After the reaction was complete, the crude product was purified by reverse-phase liquid chromatography (40 g C18 column, elution conditions of approximately 30% MeCN in water (0.1% FA), 20 min) to obtain Compound 4 (1.5 g, 2.620 mmol, yield 67.146%) in the form of a white solid.
[0360] LCMS: m / z = 595.4 (M+H)+
[0361] NaBH4 (132.163 mg, 3.493 mmol, 123.056 μL, 2 equivalents) was added to a 15 mL methanol solution of Compound 4 (1 g, 1.747 mmol, 1 equivalent) at 0 °C. The reaction mixture was stirred at 25 °C for 3 hours. LCMS analysis confirmed that the starting material was completely consumed and the mass of the target compound was determined. The reaction mixture was concentrated under reduced pressure to obtain the residue. The obtained residue was purified by reverse-phase liquid chromatography (40 g C18 column, 40%-60% MeCN elution conditions in water (0.1% FA), 20 min) to obtain Compound 5 (600 mg, 1.044 mmol, yield 59.789%) in the form of a white solid.
[0362] LCMS: m / z = 592.4 (M+H2O)+
[0363] Compound 6 (397.123 mg, 1.305 mmol, 1.5 equivalents) and DIPEA (337.431 mg, 2.611 mmol, 454.758 μL, 3 equivalents) were added to a 15 mL DMF solution of Compound 5 (500 mg, 870.278 μmol, 1 equivalent) at room temperature. The reaction mixture was stirred at 25 °C for 3 hours. LCMS analysis confirmed that the starting materials were completely consumed and the mass of the target compound was determined. The reaction mixture was concentrated under reduced pressure to obtain the residue. The obtained residue was purified by reverse-phase liquid chromatography (40 g C18 column, 60%-80% MeCN elution conditions in water (0.1% FA), 20 min) to obtain Compound 7 (500 mg, 676.012 μmol, yield 77.678%) in the form of a white solid.
[0364] LCMS: m / z = 757.6 (M+H2O)+
[0365] DIEA (209.687 mg, 1.622 mmol, 282.597 μL, 3 equivalents), HOBt (109.614 mg, 811.215 μmol, 1.5 equivalents), and Compound 8 (235.494 mg, 540.810 μmol, 1 equivalent) were added to a solution of Compound 7 (400 mg, 540.810 μmol, 1 equivalent) in DMF (6 mL) and Py (2 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 3 hours. LCMS analysis confirmed that the starting materials were completely consumed and the mass of the target compound was determined. The residue was obtained by concentrating the reaction mixture under reduced pressure. The obtained residue was purified using reverse-phase liquid chromatography (40 g C18 column, 60%-80% MeCN elution conditions in water (0.1% FA), 20 min) to obtain compound 9 in the form of a white solid (60 mg, 63.435 μmol, yield 65.717%).
[0366] LCMS: m / z =1035.970 (M+H)+
[0367] Pd / C (10% on Carbon, moistened with approximately 55% water) (20.545 mg, 193.056 μmol, 2 equivalents) was added to a methanol (6 mL) solution of Compound 9 (100 mg, 96.528 μmol, 1 equivalent) under a nitrogen atmosphere. The suspension was degassed under reduced pressure and then purged with hydrogen three times. Subsequently, the reaction mixture was stirred at 25 °C for 16 hours under a hydrogen balloon atmosphere. LCMS analysis confirmed that the starting material was completely consumed and the mass of the target compound was verified. The reaction mixture was concentrated under reduced pressure to obtain the residue. The obtained residue was purified by reverse-phase liquid chromatography (40 g C18 column, 40%-60% MeCN elution conditions in water (0.1% FA), 20 min) to obtain Compound 10 (60 mg, 63.435 μmol, yield 65.717%) in the form of a white solid.
[0368] LCMS: m / z = 946.7 (M+H)+
[0369] Compound 11 (32.519 mg, 63.435 μmol, 1 equivalent), PyBOP (66.022 mg, 126.870 μmol, 2 equivalents), and DIEA (24.596 mg, 190.306 μmol, 33.148 μL, 3 equivalents) were added to a 5 mL DMF solution of Compound 10 (60 mg, 63.435 μmol, 1 equivalent) at 0 °C. The reaction mixture was stirred at 25 °C for 3 hours. LCMS analysis confirmed that the starting materials were completely consumed and the mass of the target compound was determined. The residue was obtained by concentrating the reaction mixture under reduced pressure. The obtained residue was purified using reverse-phase liquid chromatography (40 g C18 column, elution conditions of about 60% MeCN in water (0.1% FA), 20 min) to obtain compound 12 in the form of a white solid (60 mg, 41.653 μmol, yield 65.663%).
[0370] LCMS: m / z =1441.1 (M+H)+
[0371] LiOH·H2O (8.74 mg, 208.47 μmol, 5 equivalents) was added to a THF (3 mL) and H2O (2 mL) solution of Compound 12 (60 mg, 41.69 μmol, 1 equivalent) at 0 °C. The reaction mixture was stirred at 25 °C for 3 hours. LCMS analysis confirmed that the starting material was completely consumed and the mass of the target compound was determined. The reaction mixture was concentrated under reduced pressure to obtain the residue. The obtained residue was purified by reverse-phase liquid chromatography (40 g C18 column, elution conditions of approximately 30% MeCN in water (0.1% FA), 20 min) to obtain Compound 13 (15 mg, 16.819 μmol, yield 55.613%) in the form of a white solid.
[0372] LCMS: m / z =1301.0 (M+H)+
[0373] TFA (0.6 mL) was added to a DCM (3 mL) solution of Compound 13 (30 mg, 30.243 μmol, 1 equivalent) at 0 °C. The reaction mixture was stirred at 25 °C for 3 hours. LCMS analysis confirmed that the starting material was completely consumed and the mass of the target compound was determined. The reaction mixture was concentrated under reduced pressure to obtain the residue. The obtained residue was purified by reverse-phase liquid chromatography (40 g C18 column, elution conditions of approximately 30% MeCN in water (0.1% FA), 20 min) to obtain Compound 14 (15 mg, 16.819 μmol, yield 55.613%) in the form of a white solid.
[0374] LCMS: m / z =1201.0 (M+H)+
[0375] Compound 15 (3.853 mg, 12.498 μmol, 1 equivalent) and DIPEA (1.615 mg, 12.498 μmol, 2.177 μL, 1 equivalent) were added to a 3 mL DMF solution of Compound 14 (15 mg, 12.498 μmol, 1 equivalent) at 0 °C. The reaction mixture was stirred at 25 °C for 3 hours. LCMS analysis confirmed that the starting materials were completely consumed and the mass of the target compound was determined. The reaction mixture was concentrated under reduced pressure to obtain the residue. The obtained residue was purified using prep-HPLC (ZORBAX Eclipse Plus C18 30 × 150 mm, 5 μm, mobile phase: MeCN / H2O (0.1% FA) = 38-45%) to obtain LP7 (8 mg, 5.741 μmol, yield 45.939%) in the form of a white solid.
[0376] LCMS: calculated [M / 2+Na]+ = 1394.12, found 1394.6.
[0377] 1H NMR (400 MHz, DMSO-d6) δ ppm 0.84 - 0.91 (m, 3 H) 1.12 - 1.22 (m, 2 H) 1.42 - 1.51 (m, 4 H) 1.82 - 1.91 (m, 2 H) 2.00 - 2.05 (m, 2 H) 2.15 - 2.23 (m, 2 H) 2.36 - 2.41 (m, 3 H) 3.12 - 3.22 (m, 6 H) 3.49 (br d, J=1.47 Hz, 27 H) 3.49 - 3.50 (m, 1 H) 3.52 - 3.57 (m, 7 H) 3.92 - 4.02 (m, 1H) 5.03 - 5.19 (m, 4 H) 5.20 - 5.35 (m, 4 H) 5.36 - 5.51 (m, 4 H) 5.61 - 5.82 (m, 1 H) 6.45 - 6.58 (m, 1 H) 6.93 - 7.06 (m, 2 H) 7.24 - 7.34 (m, 2 H) 7.50 - 7.61 (m, 1 H) 7.78 (br d, J=11.00 Hz, 1 H) 7.80 - 7.87 (m, 2 H) 8.02 - 8.14 (m, 1 H) 8.26 - 8.37 (m, 1 H)
[0378] The chemical structures of LP1 to LP7 synthesized in this way are as follows.
[0379] LP1: PEG8-VA-Exa
[0380]
[0381] LP2: PEG8-VCit-Exa
[0382]
[0383] LP3: PEG8-BG-Exa
[0384]
[0385] LP4: PSAR10-BG-Exa
[0386]
[0387] LP5: BG-Exa
[0388]
[0389] LP6: mBG-Exa
[0390]
[0391] LP7: PEG8-mBG-Exa
[0392]
[0393]
[0394] Example 2: ADC Fabrication and Characterization
[0395] An ADC was prepared by conjugating the LP obtained by the method of Example 1 with an antibody.
[0396] To prepare ADC1 (Batch No.: WBPX1091-231122001), 980.4 μL of DTPA (10 mM solution dissolved in ultrapure water) was added to 3.70 mL of monoclonal antibody Ab1 (antibody solution dissolved at 4.32 mg / mL in PBS (pH 7.4)) to make the final concentration of DTPA 2 mM. Subsequently, 217.69 μL of TCEP (5 mM solution dissolved in ultrapure water) was added at 22°C to achieve an Ab1:TCEP molar ratio of 1:10, making the final concentration of the antibody 3.26 mg / mL, and the reduction reaction was carried out at 22°C at 60 rpm for 16 hours. Next, 392.39 μL of DMA and 152.38 μL of LP1 (10 mM stock solution dissolved in DMA) were slowly added in an ice-water bath with gentle stirring to achieve an antibody:LP molar ratio of 1:14, with a final organic solvent ratio of 10.0%. At this point, the antibody concentration in the conjugation solution was 2.94 mg / mL, and the reaction solution was reacted at 22°C at 60 rpm for 1 hour. Subsequently, 87.1 μL of NAC solution (10 mM solution dissolved in ultrapure water) was added at 22°C for 0.5 hours to achieve an antibody:NAC molar ratio of 1:8, thereby terminating the reaction. The conjugation solution was purified using an Amicon Ultra centrifuge filter (Amicon, 15 mL, 50 kDa MWCO) and exchanged with 20 mM His-AcOH (pH 5.5) buffer. The final solution was filtered through a 0.22 μm PVDF disposable filter to obtain the final ADC1. The product was analyzed using LC-MS, SEC-HPLC, HIC-HPLC, RP-HPLC, BCA assay, and kinetic turbidimetric assay (KTA).
[0397] To prepare ADC2 (Batch No.: WBPX1091-231122003), 39.6 μL of EDTA (200 mM solution dissolved in ultrapure water) was added to 3.70 mL of monoclonal antibody Ab1 (antibody solution dissolved at 4.32 mg / mL in PBS (pH 7.4)) to make the final concentration of EDTA 2 mM. Subsequently, 217.69 μL of TCEP (5 mM solution dissolved in ultrapure water) was added at 22°C to achieve an Ab1:TCEP molar ratio of 1:10, making the final concentration of the antibody 4.04 mg / mL, and the reduction reaction was carried out at 22°C at 60 rpm for 16 hours. Next, 287.78 μL of DMA and 152.38 μL of LP2 (10 mM stock solution dissolved in DMA) were slowly added in an ice-water bath with gentle stirring to achieve an antibody:LP molar ratio of 1:14, with a final organic solvent ratio of 10.0%. At this point, the antibody concentration in the conjugation solution was 3.64 mg / mL, and the reaction solution was reacted at 22°C at 60 rpm for 1 hour. Subsequently, 54.4 μL of NAC solution (10 mM solution dissolved in ultrapure water) was added at 22°C for 0.5 hours to achieve an antibody:NAC molar ratio of 1:5, thereby terminating the reaction. The conjugation solution was purified using an Amicon Ultra centrifuge filter (Amicon, 15 mL, 50 kDa MWCO) and exchanged with 20 mM His-AcOH (pH 5.5) buffer. The final solution was filtered through a 0.22 μm PVDF disposable filter to obtain the final ADC2. The product was analyzed using LC-MS, SEC-HPLC, HIC-HPLC, RP-HPLC, BCA assay, and kinetic turbidimetric assay (KTA).
[0398] To prepare ADC3 (Batch No.: WBPX1091-240513002), 101.23 μL of EDTA (200 mM solution dissolved in ultrapure water) was added to 1.46 mL of monoclonal antibody Ab1 (antibody solution dissolved at 5.48 mg / mL in PBS (pH 7.4)) to make the final concentration of EDTA 2 mM. Subsequently, 119.73 μL of TCEP (5 mM solution dissolved in ultrapure water) was added at 22°C to achieve an Ab1:TCEP molar ratio of 1:11, making the final concentration of the antibody 5.01 mg / mL, and the reduction reaction was carried out at 22°C at 60 rpm for 16 hours. Next, 101.23 μL of DMA and 76.19 μL of LP3 (10 mM stock solution dissolved in DMA) were slowly added in an ice-water bath with gentle stirring to achieve an antibody:LP molar ratio of 1:14, with a final organic solvent ratio of 10.0%. At this point, the antibody concentration in the conjugation solution was 4.51 mg / mL, and the reaction solution was reacted at 22°C at 60 rpm for 1 hour. Subsequently, 38.10 μL of NAC solution (10 mM solution dissolved in ultrapure water) was added at 22°C for 0.5 hours to achieve an antibody:NAC molar ratio of 1:7, thereby terminating the reaction. The conjugation solution was purified using an Amicon Ultra centrifuge filter (Amicon, 15 mL, 50 kDa MWCO) and exchanged with 20 mM His-AcOH (pH 5.5) buffer. The final solution was filtered through a 0.22 μm PVDF disposable filter to obtain the final ADC3. The product was analyzed using LC-MS, SEC-HPLC, HIC-HPLC, RP-HPLC, BCA assay, and kinetic turbidimetric assay (KTA).
[0399] To prepare ADC4 (Batch No.: WBPX1091-240506002), 23.9 μL of EDTA (200 mM solution dissolved in ultrapure water) was added to 2.19 mL of monoclonal antibody Ab1 (antibody solution dissolved at 5.48 mg / mL in PBS (pH 7.4)) to make the final concentration of EDTA 2 mM. Subsequently, 179.59 μL of TCEP (5 mM solution dissolved in ultrapure water) was added at 22°C to achieve an Ab1:TCEP molar ratio of 1:11, making the final concentration of the antibody 5.01 mg / mL, and the reduction reaction was carried out at 22°C at 60 rpm for 16 hours. Next, 143.61 μL of DMA and 122.45 μL of LP4 (10 mM stock solution dissolved in DMA) were slowly added in an ice-water bath with gentle stirring to achieve an antibody:LP molar ratio of 1:14, with a final organic solvent ratio of 10.0%. At this point, the antibody concentration in the conjugation solution was 4.51 mg / mL, and the reaction solution was reacted at 22°C at 60 rpm for 1 hour. Subsequently, 81.63 μL of NAC solution (10 mM solution dissolved in ultrapure water) was added at 22°C for 0.5 hours to achieve an antibody:NAC molar ratio of 1:10, thereby terminating the reaction. The conjugation solution was purified using an Amicon Ultra centrifuge filter (Amicon, 15 mL, 50 kDa MWCO) and exchanged with 20 mM His-AcOH (pH 5.5) buffer. The final solution was filtered through a 0.22 μm PVDF disposable filter to obtain the final ADC4. The product was analyzed using LC-MS, SEC-HPLC, HIC-HPLC, RP-HPLC, BCA assay, and kinetic turbidimetric assay (KTA).
[0400] To prepare ADC5 (Batch No.: WBPX1091-231122002), 980.4 μL of DTPA (10 mM solution dissolved in ultrapure water) was added to 3.70 mL of monoclonal antibody Ab1 (antibody solution dissolved at 4.32 mg / mL in PBS (pH 7.4)) to make the final concentration of DTPA 2 mM. Subsequently, 217.69 μL of TCEP (5 mM solution dissolved in ultrapure water) was added at 22°C to achieve an Ab1:TCEP molar ratio of 1:10, making the final concentration of the antibody 3.26 mg / mL, and the reduction reaction was carried out at 22°C at 60 rpm for 16 hours. Next, 381.51 μL of DMA and 163.27 μL of LP5 (10 mM stock solution dissolved in DMA) were slowly added in an ice-water bath with gentle stirring to achieve an antibody:LP molar ratio of 1:15, with a final organic solvent ratio of 10.0%. At this point, the antibody concentration in the conjugation solution was 2.94 mg / mL, and the reaction solution was reacted at 22°C at 60 rpm for 1 hour. Subsequently, 87.1 μL of NAC solution (10 mM solution dissolved in ultrapure water) was added at 22°C for 0.5 hours to achieve an antibody:NAC molar ratio of 1:8, thereby terminating the reaction. The conjugation solution was purified using an Amicon Ultra centrifuge filter (Amicon, 15 mL, 50 kDa MWCO) and exchanged with 20 mM His-AcOH (pH 5.5) buffer. The final solution was filtered through a 0.22 μm PVDF disposable filter to obtain the final ADC5. The product was analyzed using LC-MS, SEC-HPLC, HIC-HPLC, RP-HPLC, BCA assay, and kinetic turbidimetric assay (KTA).
[0401] To prepare ADC6 (Batch No.: WBPX1091-240819001), 8.30 μL of EDTA (200 mM solution dissolved in ultrapure water) was added to 715.8 μL of monoclonal antibody Ab1 (antibody solution dissolved at 13.97 mg / mL in 20 mM His-AcOH (pH 5.5) containing 150 mM NaCl) to make the final concentration of EDTA 2 mM. Subsequently, 109.30 μL of TCEP (5 mM solution dissolved in ultrapure water) was added at 22°C to achieve an Ab1:TCEP molar ratio of 1:8 to make the final concentration of the antibody 12.0 mg / mL, and the reduction reaction was carried out at 22°C at 60 rpm for 16 hours. Next, 81.97 μL of DMA and 81.97 μL of LP6 (a 10 mM stock solution dissolved in DMA) were slowly added in an ice-water bath with gentle stirring to achieve an antibody:LP molar ratio of 1:12, with a final organic solvent ratio of 10.0%. At this point, the antibody concentration in the conjugation solution was 10.80 mg / mL, and the reaction solution was reacted at 22°C at 60 rpm for 1 hour. Subsequently, 54.65 μL of NAC solution (a 10 mM solution dissolved in ultrapure water) was added at 22°C for 0.5 hours to achieve an antibody:NAC molar ratio of 1:8, thereby terminating the reaction. The conjugation solution was purified using an Amicon Ultra centrifuge filter (Amicon, 15 mL, 50 kDa MWCO) and exchanged with 20 mM His-AcOH (pH 5.5) buffer. The final solution was filtered through a 0.22 μm PVDF disposable filter to obtain the final ADC6. The product was analyzed using LC-MS, SEC-HPLC, HIC-HPLC, RP-HPLC, BCA assay, and kinetic turbidimetric assay (KTA).
[0402] To prepare ADC8 (Batch No.: WBPX1091-251202001), 99.49 μL of EDTA (200 mM solution dissolved in ultrapure water) was added to 9.28 mL of trastuzumab (TRA-Step 2, antibody solution dissolved at 5.61 mg / mL in PBS (pH 7.4)) to make the final concentration of EDTA 2 mM. Subsequently, 572.21 μL of TCEP (5 mM solution dissolved in ultrapure water) was added at 22°C to achieve a trastuzumab:TCEP molar ratio of 1:8, making the final antibody concentration 5.23 mg / mL, and the reduction reaction was carried out at 22°C at 60 rpm for 16 hours. Next, 325.15 μL of DMSO and 206.33 μL of LP7 (10 mM stock solution dissolved in DMSO) were slowly added to 4.78 mL (5.23 mg / mL) of reduced antibody with gentle stirring in an ice-water bath to achieve an antibody:LP molar ratio of 1:12, until the final organic solvent ratio was 10.0%. The antibody concentration in the conjugation solution was 4.71 mg / mL, and the reaction solution was reacted at 22°C at 60 rpm for 1 hour. Subsequently, 206.33 μL of NAC solution (10 mM solution dissolved in ultrapure water) was added at 22°C for 0.5 hours to achieve an antibody:NAC molar ratio of 1:12, thereby terminating the reaction. The conjugation solution was purified using an Amicon Ultra centrifuge filter (Amicon, 15 mL, 50 kDa MWCO) and exchanged with 20 mM histidine / histidine-HCl, 8% sucrose (pH 6.0) buffer. The final solution was filtered through a 0.22 μm PVDF disposable filter to obtain the final ADC8. The product was analyzed using LC-MS, SEC-HPLC, HIC-HPLC, RP-HPLC, BCA assay, and kinetic turbidimetric assay (KTA).
[0403] To prepare ADC9 (Batch No.: WBPX1091-251202002), 99.49 μL of EDTA (200 mM solution dissolved in ultrapure water) was added to 9.28 mL of trastuzumab (TRA-Step 2, antibody solution dissolved at 5.61 mg / mL in PBS (pH 7.4)) to make the final concentration of EDTA 2 mM. Subsequently, 572.21 μL of TCEP (5 mM solution dissolved in ultrapure water) was added at 22°C to achieve a trastuzumab:TCEP molar ratio of 1:8, making the final antibody concentration 5.23 mg / mL, and the reduction reaction was carried out at 22°C at 60 rpm for 16 hours. Next, 337.58 μL of DMSO and 214.21 μL of LP6 (10 mM stock solution dissolved in DMSO) were slowly added to 4.97 mL (5.23 mg / mL) of reduced antibody with gentle stirring in an ice-water bath to achieve an antibody:LP molar ratio of 1:12, until the final organic solvent ratio was 10.0%. The antibody concentration in the conjugation solution was 4.70 mg / mL, and the reaction solution was reacted at 22°C at 60 rpm for 1 hour. Subsequently, 214.21 μL of NAC solution (10 mM solution dissolved in ultrapure water) was added at 22°C for 0.5 hours to achieve an antibody:NAC molar ratio of 1:12, thereby terminating the reaction. The conjugation solution was purified using an Amicon Ultra centrifuge filter (Amicon, 15 mL, 50 kDa MWCO) and exchanged with 20 mM histidine / histidine-HCl, 8% sucrose (pH 6.0) buffer. The final solution was filtered through a 0.22 μm PVDF disposable filter to obtain the final ADC9. The products were analyzed using LC-MS, SEC-HPLC, HIC-HPLC, RP-HPLC, BCA assay, and kinetic turbidimetric assay (KTA). The ADCs produced by the above conjugation method are as follows.
[0404] ADC1: Includes LP1 and the anti-ROBO1 antibody Ab1.
[0405] ADC2: Includes LP2 and the anti-ROBO1 antibody Ab1.
[0406] ADC3: Includes LP3 and the anti-ROBO1 antibody Ab1.
[0407] ADC4: Includes LP4 and the anti-ROBO1 antibody Ab1.
[0408] ADC5: Includes LP5 and the anti-ROBO1 antibody Ab1.
[0409] ADC6: Includes LP6 and the anti-ROBO1 antibody Ab1.
[0410] ADC7: Includes LP6 and anti-ROBO1 antibody Ab2.
[0411] ADC8: Includes LP7 and the anti-HER2 antibody trastuzumab.
[0412] ADC9: Includes LP6 and the anti-HER2 antibody trastuzumab.
[0413] The heavy and light chain amino acid sequences of the anti-ROBO1 antibody Ab1 used in the manufacture of the above ADC are as follows.
[0414] Ab1 heavy chain:
[0415] QVQLVQSGAEVKKPGASVKVSCKASGYIFTSYAMHWVRQAPGQRLEWMGWVNAGRGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARDGGNYPGAFDIWGQGTMVTVSS (SEQ ID NO: 1)
[0416] Ab1 light chain:
[0417] DVVLTQSPLSLPVTLGQPASISCRSSQSLVYSEGNTYLDWFQQRPGQSPRRLIYKVSKRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQGIYWPLTFGGGTKVEIK (SEQ ID NO: 2)
[0418] Ab2 is an anti-ROBO1 antibody, and its sequence is different from Ab1.
[0419] Antibody Ab1 and antibody Ab2 had purity levels of 96.99% and 100%, respectively, as measured by Size Exclusion Chromatography-High Performance Liquid Chromatography (SEC-HPLC), meeting the internal standard of 95% or higher.
[0420] The purity of trastuzumab was also 99.49%, meeting internal standards.
[0421] The monomer purity of all obtained ADCs was over 97% (measured by SEC-HPLC).
[0422] The target Drug-Antibody Ratio (DAR) was 8, and in fact, all DAR values measured by Liquid Chromatography / mass spectrometry (LC / MS) satisfied this. Both free drug and endotoxin met internal criteria.
[0423] The characteristic analysis values of the manufactured ADCs are as shown in [Table 1] below and are also shown in Figures 1 to 16.
[0424] ADCBatchMS-DARMonomer (%)Free drug(%mol / mol)Endo (EU / mg)ADC1WBPX1091-2311220017.9198.44<0.200.626ADC2WBPX1091-2311220037.8798.04<0.48 0.331ADC3WBPX1091-2405130027.8697.990.11<0.100ADC4WBPX1091-2405060027.9098.930.63<0. 165ADC5WBPX1091-2311220028.0298.090.350.224ADC6WBPX1091-2408190017.9199.69<0.13<0.19 3ADC8WBPX1091-2512020018.0799.79<0.17<0.217ADC9WBPX1091-2512020028.0099.32<0.11<0.142
[0425] All manufactured ADCs met internal quality standards for DAR, monomer purity, free drug, and endotoxin, and it was confirmed that the quality characteristics among the ADCs were uniform, making them suitable for subsequent comparative experiments.
[0426]
[0427] Example 3: Hydrophobicity Analysis I
[0428] Hydrophobic Interaction Chromatography (HIC) analysis was performed to analyze the hydrophobicity of the prepared ADCs. For the analysis, unconjugated naked antibodies and six prepared ADCs (ADC1 to ADC6) were diluted to a concentration of 1 mg / mL in a pH 7.2 PBS solution. 10 μL of the diluted samples were loaded onto a TSK-Gel Butyl-NPR column 4.6 x 35 mm (Tosoh Bioscience). Elution was performed using a linear gradient by replacing 100% mobile phase A: 25 mM potassium phosphate, 1.5 M ammonium sulfate, pH 7.0, with 100% mobile phase B: 85% 25 mM potassium phosphate, 15% isopropanol, pH 7.0 over 15 minutes. The flow rate was set to 0.6 mL / min, the sample temperature to 4℃, and the column temperature to 25℃, and observations were performed using 280 nm UV. A Waters Arc HPLC instrument equipped with a UV / Vis detector and Empower software were used.
[0429] The experimental results are shown in Figure 17. ADCs with amino acid linkers (ADC1, ADC2) exhibited higher hydrophobicity compared to ADCs with beta-glucuronide linkers (ADC3, ADC4, ADC5). Additionally, among the ADCs with beta-glucuronide linkers, hydrophilicity was observed in the order of ADC4 > ADC5 ≈ ADC6 > ADC3, confirming that while the polysarcosine unit most improved the hydrophilicity of ADCs with beta-glucuronide linkers, the PEG unit had a relatively low effect on improving hydrophilicity. ADC5 and ADC6, which do not contain PEG units, showed higher hydrophilicity than ADC3, which contains PEG units, which is a result different from conventional expectations.
[0430]
[0431] Example 4: Hydrophobicity Analysis II
[0432] Hydrophobic interaction chromatography (HIC) analysis was performed on two antibody-drug conjugates (ADC8 and ADC9) based on a beta-glucuronide linker conjugated with the anti-HER2 antibody trastuzumab. The two antibody-drug conjugates were diluted to a maximum of 8 μL and loaded into a TSK-gel butyl-NPR column 4.6*35 mm (Tosoh Bioscience) at a volume of 30-40 μg. Using a linear gradient, elution was performed by replacing 100% mobile phase A: 50 mM dipotassium phosphate, 1.5 M ammonium sulfate, pH 7.1, with mobile phase B: 75% 21.3 mM potassium phosphate, 28.6 mM dipotassium phosphate, 25% isopropanol, pH 7.4 over 15 minutes. The flow rate was set to 0.6 mL / min, the sample temperature to 4℃, and the column temperature to 25℃, and observations were performed using 280 nm UV. An Agilent 1260 instrument and Agilent Control Panel for Openlab Software (Version 3.5) were used.
[0433] The experimental results are shown in Fig. 18. Similar to the results in Fig. 17, ADC9 (Trastuzumab-mBG-Exa), an ADC having a beta-glucuronide linker that does not contain a PEG unit, showed higher hydrophilicity than ADC8 (Trastuzumab-PEG8-mBG-Exa), an ADC containing a PEG unit.
[0434]
[0435] Example 5: ADC Stability Analysis I
[0436] To evaluate the stability of LP6 under repeated freeze-thaw cycles, ADC7, conjugated with LP6 and Ab2, an anti-ROBO1 antibody with a sequence different from Ab1, was frozen at -80°C and then completely thawed at room temperature, a process repeated 1, 3, and 5 times. After each freeze-thaw cycle was completed, samples were collected and used for the following analysis. ADC7 was prepared using the same method as the preparation of ADC6 described in Example 2 above, except that Ab2 was used as the antibody.
[0437] Size Exclusion Chromatography (SEC) analysis was performed to confirm aggregate formation and changes in monomer purity. The sample was diluted to a concentration of 1 mg / mL in PBS solution at pH 7.2, and 10 μL of the diluted sample was injected into an Xbridge Premier Protein SEC column (Waters). The mobile phase was set to PBS (pH 7.4), the flow rate to 0.5 mL / min, the sample temperature to 4°C, and the column temperature to 25°C, and detection was performed at 280 nm UV. The analysis was conducted for 30 minutes using a Waters Arc HPLC instrument equipped with a UV / Vis detector and Empower software.
[0438] Hydrophobic interaction chromatography (HIC) analysis was performed to evaluate changes in the drug-antibody ratio (DAR) and hydrophobicity. The HIC analysis was performed in the same manner as described in "Example 3: Hydrophobicity Analysis I".
[0439] The experimental results are shown in Figures 19 to 24. No aggregation of ADC or changes in monomer purity were observed even after repeated freeze-thaw cycles, and the DAR and hydrophobicity profiles also remained at levels equivalent to the initial values. These results indicate that ADC7 containing LP6 maintains physicochemical stability even under repeated freeze-thaw conditions. The results of each experiment are summarized in Table 2.
[0440] Sample nameConditionsUV280SEC-HPLCHIC-HPLCTimes of F / Tmg / mLHMW%Main%LMW%HMW%Main%LMW%ADC711mg / mL(diluted in PBS)0.2696.403.340100030.0797.572.360100050.0797.892.0401000
[0441]
[0442] Example 6: In vitro serum stability analysis
[0443] To confirm the stability of ADC7 in the serum of three species—mice, monkeys, and humans—the samples were treated as follows.
[0444] The pooled frozen serum was thawed at 37°C prior to the experiment and centrifuged at 4000 rpm for 5 minutes to remove any coagulations present. Subsequently, the sample and blank serum were thoroughly mixed to achieve a final concentration of 100 μg / mL, and the mixed serum working solution was dispensed into 1.5 mL microcentrifuge tubes (Days 0, 1, 2, 4, and 7). Each reaction tube was incubated at 37°C for a set time. After the incubation was complete, the reaction was stopped by adding a stop solution (20 ng / mL of tolbutamide in acetonitrile) and mixing thoroughly. Afterward, each microcentrifuge tube was centrifuged at 4000xg for 20 minutes, the supernatant was collected, and an ELISA was performed to measure total antibody and ADC concentrations. For antibody measurement, human ROBO1 protein (ACRO, Cat #: RB1-H52H3) was used as the capture antigen, and for ADC measurement, anti-exatecan antibody (NOVO PRO, Cat #: 176731) was used as the capture antibody, and goat-derived anti-human IgG-HRP antibody (Southernbiotech, Cat #: 2049-05) with minimized cross-reactivity to rhusus and cynomolgus monkey proteins was used as the detection antibody.
[0445] The analysis results are shown in Figure 25. Total antibody and ADC concentrations in mouse, monkey, and human serum remained unchanged during 7 days of incubation. This indicates that the deconjugation and degradation of ADCs under serum conditions are limited, suggesting that LP6-based ADC7 exhibits stable behavior in a serum environment.
[0446]
[0447] Example 7: In vitro cell death ability test
[0448] To verify the apoptotic ability of the synthesized ADCs, the Cell Count Kit-8 (CCK-8) method, which allows for the quantitative analysis of living cells through metabolic enzymatic reactions, was utilized. For this purpose, NCI-H446 (ATCC, #HTB-171), a human cancer-derived lung cancer cell line expressing human ROBO1 protein, was cultured in RPMI medium containing 10% fetal bovine serum (FBS). The day before treatment with the ADC samples, NCI-H446 cells were plated in 96-well white microplates at a density of 5,000 cells per well (90 μL), and 90 μL of RPMI medium was added to the control wells that were empty of cells. The plates were then incubated overnight in a cell incubator at 37°C under 5% CO2 conditions. Reference samples of Ab1 and IgG1, which are naked antibodies not conjugated with the ADCs or drugs, were diluted in PBS and treated at a dose of 10 μL per well. To confirm sensitivity to the drug, 10 μL of exatecan was added to the positive control wells, and 10 μL of PBS was added to the negative control wells that did not contain the sample. After incubating the cells in a cell culture incubator at 37°C and 5% CO2 for 3 days, 10 μL of CCK-8 reagent was added to each well, and the cells were incubated at 37°C for 3 hours. The resulting color signal was measured using a microplate reader. The experimental results were processed into IC50 values using GraphPad Prism software.
[0449] The results of the in vitro activity (IC50 (nM)) of each ADC are summarized in [Table 3] below.
[0450] Ab1IsotypeHuman IgGADC3ADC4ADC51st No efficacy No efficacy 38.38 nM15.94 nM15.62 nM2nd No efficacy No efficacy 33.02 nM10.38 nM12.47 nM
[0451] As expected, no cytotoxic effects were observed on NCI-H446 cells for the naked antibody Ab1 and human IgG1 antibody without LP linkage. ADC3, which is attached with PEG 8 molecules known to improve physical properties by lowering the hydrophobicity of ADCs, consistently exhibited an in vitro cytotoxic effect that was approximately 2-3 times lower than that of ADC5 without PEG linkage. On the other hand, ADC4, which is attached with polysarcosine residues known to similarly lower hydrophobicity, showed an in vitro cytotoxic effect of the same degree as ADC5. These results suggest that, at least for ADCs containing beta-glucuronide linkers, PEGylation can have an adverse effect on the efficacy of the ADC.
[0452]
[0453] Example 8: In vivo tumor suppression effect test I
[0454] The tumor growth inhibitory efficacy of three ROBO1 ADCs (ADC4, ADC5, and ADC6) was evaluated in NCI-H1048, a human small cell lung cancer (SCLC) xenograft tumor model expressing ROBO1. The three ADCs were administered intravenously (IV) at a dose of 5 mg / kg to female athymic nude mice (BALB / c nude) with established NCI-H1048 tumors (~100 mm3). Each group consisted of 5 mice. The effect of each ADC on NCI-H1048 tumor growth was measured up to day 18 after drug administration.
[0455] As shown in Fig. 26, the experimental results indicated that ADC6, without a PEG unit attached, exhibited a superior tumor suppression effect compared to ADC4, with a PSAR unit attached. Although ADC4 displayed the best characteristics in terms of hydrophilicity (Fig. 17), its actual tumor suppression effect was only lower than that of ADC6. These results are believed to be, for instance, due to the PSAR unit increasing the size (molecular weight) of the ADC and consequently reducing its penetration into solid tumors. Since all tested ADCs showed no toxicity and no effect on body weight changes, drug administration was well tolerated. Meanwhile, among the ADCs without a PEG unit attached, ADC6 showed a superior tumor suppression effect compared to ADC5 (Fig. 27). This suggests that the tumor suppression effect can be further improved depending on the structure of the stretcher unit connected to the glucuronide unit.
[0456]
[0457] Example 9: In vivo tumor suppression effect test II
[0458] Since a dose of 5 mg / kg is sufficiently high for tumor growth inhibition in the NCI-H1048 xenograft tumor model, a lower dose of 2.5 mg / kg was applied to facilitate the comparison of the effects of each linker on tumor growth inhibition. Female athymic nude mice (BALB / c nude) with established NCI-H1048 tumors (~100 mm³) were administered the vehicle and two types of ADCs (ADC5 and ADC6) by intravenous (IV) injection at a dose of 2.5 mg / kg. The size of each group was 5 mice. The treatment effect of each ADC on NCI-H1048 tumor growth was measured until day 14 after drug administration.
[0459] As shown in Figure 28, when the 14th day after drug administration was reached, the tumor growth inhibitory efficacy of ADC6 was superior to that of ADC5, and the difference was much more evident than when 5 mg / kg was administered. During the observation period, the drugs showed no toxicity and normal body weight gain, so drug administration was well tolerated. These experimental results once again demonstrated that the tumor inhibitory effect can be further improved depending on the structure of the stretcher unit connected to the glucuronide unit.
[0460]
[0461] Example 10: Comparative test with Enhertu®
[0462] To confirm whether LP6 maintains its efficacy even when bound to other antibodies, an ADC9 was prepared by conjugating LP6 to an anti-HER2 antibody (Trastuzumab), and its tumor growth inhibitory efficacy was evaluated in a xenograft tumor model transplanted with JIMT-1, a human breast cancer (BC) cell line expressing HER2. Enhertu (Trastuzumab deruxtecan; manufactured by Daiichi Sankyo, Batch number: 426595) was used as the control group.
[0463] Two types of ADCs were administered intravenously (IV) twice a week to female NOD scid (NOD.CB17-Prkdc / NCrHsd) mice with established JIMT-1 tumors (~100 mm³). Enhertu was administered at 10 mg / kg, a dose known to produce sufficient efficacy in JIMT-1, while ADC9, an LP6-conjugated Trastuzumab ADC, was administered at 10 mg / kg or a lower dose of 5 mg / kg. Each group consisted of 5 mice. The effect of each ADC on JIMT-1 tumor growth was measured up to day 31 after drug administration.
[0464] As shown in Figure 29, the experimental results showed that ADC9 (Trastuzumab-mBG-Exa) exhibited a superior tumor suppression effect compared to Enhertu at the same dose (10 mg / kg), and from day 14, ADC9 at half the dose (5 mg / kg) showed a tumor suppression effect similar to that of Enhertu. No significant toxicity or changes in body weight were observed in any of the tested ADCs, indicating that the drug administration was generally well tolerated. These results demonstrate that LP6 according to the present invention maintains its efficacy even when bound to other antibodies in addition to the anti-ROBO1 antibody, and can exhibit superior tumor suppression efficacy compared to the linker-payload used in Enhertu, which is widely used in clinical practice as an approved ADC.
Claims
1. An antibody-drug conjugate comprising the following chemical formula 1 or chemical formula 2, characterized by comprising a beta-glucuronide-linker and not comprising polyethylene glycol: <Chemical Formula 1> <Chemical Formula 2> Among the above formulas, Su stands for sugar moiety, and The L residue is a stretcher unit that is directly or indirectly linked to an antibody, and n and m are integers of 0 or 1, respectively; if n is 0, m is 1, and if n is 1, m is 0, and The Y residue is a self-immolative spacer unit and is directly or indirectly connected to residues derived from the drug.
2. An antibody-drug conjugate according to claim 1, wherein the L residue has the following chemical formula 3. <Chemical Formula 3> -R 1 -CONR 2 -R 3 -X- or -R 1 - NR 2 CO-R 3 -X- Among the above formulas, R 1 and R 3 are independently, C1-C 10 Alkylene-, -C1-C 10 alkenylene-, -C3-C8 carbocyclo-, -arylene-, -C1-C 10 Alkylene-arylene-, -C1-C 10 Alkenylene-arylene-, -arylene-C1-C 10 Alkylene-, -arylene-C1-C 10 alkenylene-, -C1-C 10 Alkylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkenylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-arylene-C1-C 10 alkenylene-, -C1-C 10 Alkenylene-arylene-C1-C 10 alkenylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-, -C1-C 10 Alkenylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -(C3-C8 carbocyclo)-C1-C 10 alkenylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkenylene-(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-C1-C 10 alkenylene-, -C1-C 10 Alkenylene-(C3-C8 carbocyclo)-C1-C 10 alkenylene-, -C3-C8heterocyclo-, -C1-C 10 Alkylene-(C3-C8 heterocyclo)-, -C1-C 10 Alkenylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C 10 Alkylene-, -(C3-C8 heterocyclo)-C1-C 10 alkenylene-, -C1-C 10 Alkylene-(C3-C8 heterocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkenylene-(C3-C8 heterocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 heterocyclo)-C1-C 10 alkenylene-, -C1-C 10 Alkenylene-(C3-C8 heterocyclo)-C1-C 10 Selected from the group consisting of alkenylenes, R 2 is H or a substitutable C 1-6 It is alkyl, and X does not exist, or NR 2 CO or CONR 2 lim.
3. An antibody-drug conjugate according to claim 1, wherein the sugar residue has the following chemical formula.
4. In paragraph 2, n is 1, m is 0, and X is NR 2 CO antibody-drug conjugate.
5. An antibody-drug conjugate according to claim 1, wherein the L residue comprises maleimide or a ring-opened hydrolyzed maleimide derivative, or a divalent group derived therefrom.
6. An antibody-drug conjugate comprising the following chemical formula in claim 1. (In the above formula, the maleimide residue may be ring-opened and connected to the antibody) 7. The antibody-drug conjugate according to claim 1, wherein the antibody specifically binds to a protein expressed on a tumor cell or is an antibody or its antigen-binding fragment.
8. An antibody-drug conjugate of claim 7 in which the protein expressed on the tumor cells is ROBO1 or HER2.
9. An antibody-drug conjugate according to claim 1, wherein the drug is a cytotoxic compound or an immunomodulatory compound.
10. An antibody-drug conjugate according to claim 1, wherein the drug is selected from the group consisting of carboxyl-containing drugs, thiol-containing drugs, amino-containing drugs, and hydroxyl-containing drugs.
11. An antibody-drug conjugate according to claim 1, wherein the drug is selected from the group consisting of amanitin, duocamycin, orristatin, orristatin F (AF), monomethyl orristatin F (MMAF), metansine, metansine (DM1), labtansine (DM4), tubulaisine, calikiamycin, camptothecin, SN-38, exatecan, Maaa-1181a, taxol, daunomycin, vinblastine, doxorubicin, methotrexate, pyrrolobenzodiazepine (PBD) and its dimers, indylinobenzodiazepine (IBD) and its dimers, or their radioisotopes and / or pharmaceutically acceptable salts.
12. An antibody-drug conjugate in which the drug of item 10 is exatecan or a derivative thereof.
13. A pharmaceutical composition for treating cancer comprising the antibody-drug conjugate described in claim 1.
14. A method for treating cancer comprising administering the antibody-drug conjugate described in paragraph 1 to a patient requiring treatment for cancer.
15. An antibody-drug conjugate comprising the following Formula 1 or Formula 2 containing a beta-glucuronide-linker: <Chemical Formula 1> <Chemical Formula 2> Among the above formulas, Su stands for sugar moiety, and The L residue has the following chemical formula 4 and is a stretcher unit linked directly or indirectly to an antibody, and <Chemical Formula 4> -R 4 -CONR 5 -R 6 -X- or -R 4 - NR 5 CO-R 6 -X- (Among the above formulas, R 4 and R 6 are independently, -C1-C 10 Alkylene-, -C3-C8 carbocyclo-, -arylene-, -C1-C 10 Alkylene-arylene-, -arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-arylene-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C1-C 10 Alkylene-(C3-C8 carbocyclo)-C1-C 10 Alkylene-, -C3-C8 heterocyclo-, -C1-C 10 Alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C 10 Alkylene- and -C1-C 10 Alkylene-(C3-C8 heterocyclo)-C1-C 10 Selected from the group consisting of alkylene-, and one or more of the carbon atoms of the alkylene are NR 5 , can be substituted with O or CO, and R 5 is H or a substitutable C 1-6 (Alkaline) X is NR 5 It is CO, and, n and m are integers of 0 or 1, respectively; if n is 0, m is 1, and if n is 1, m is 0, and The Y residue is a self-immolative spacer unit and is directly or indirectly connected to residues derived from the drug.
16. An antibody-drug conjugate according to claim 15, wherein the sugar residue has the following chemical formula.
17. An antibody-drug conjugate in which n is 1 and m is 0, as in paragraph 15.
18. An antibody-drug conjugate according to claim 15, wherein the L residue comprises maleimide or a ring-opened hydrolyzed maleimide derivative, or a divalent group derived therefrom.
19. An antibody-drug conjugate comprising the following chemical formula in paragraph 15. (In the above formula, the maleimide residue may be ring-opened and connected to the antibody) 20. In paragraph 15, the antibody-drug conjugate is an antibody or its antigen-binding fragment that specifically binds to a protein expressed on a tumor cell.
21. An antibody-drug conjugate in which the protein expressed on the tumor cells is ROBO1 or HER2, as described in paragraph 20.
22. An antibody-drug conjugate in which the above drug is a cytotoxic compound or an immunomodulatory compound, wherein the above drug is a cytotoxic compound or an immunomodulatory compound.
23. An antibody-drug conjugate according to claim 15, wherein the drug is selected from the group consisting of carboxyl-containing drugs, thiol-containing drugs, amino-containing drugs, and hydroxyl-containing drugs.
24. An antibody-drug conjugate according to claim 15, wherein the drug is selected from the group consisting of amanitin, duocamycin, orristatin, orristatin F (AF), monomethyl orristatin F (MMAF), metansine, methansine (DM1), ravtansine (DM4), tubulaisine, calikiamycin, camptothecin, SN-38, exatecan, Maaa-1181a, taxol, daunomycin, vinblastine, doxorubicin, methotrexate, pyrrolobenzodiazepine (PBD) and its dimers, indylinobenzodiazepine (IBD) and its dimers, or their radioisotopes and / or pharmaceutically acceptable salts.
25. An antibody-drug conjugate in which the drug of paragraph 23 is exatecan or a derivative thereof.
26. A pharmaceutical composition for treating cancer comprising the antibody-drug conjugate described in paragraph 15.
27. A method for treating cancer comprising administering the antibody-drug conjugate described in paragraph 15 to a patient requiring treatment for cancer.
